<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html id="nojs" xmlns="http://www.w3.org/1999/xhtml" xmlns:m="http://www.w3.org/1998/Math/MathML" xmlns:og="http://ogp.me/ns#" xml:lang="en-GB" lang="en-GB" xmlns:wb=“http://open.weibo.com/wb”>

<head>

   
  
      
  
                  
  
                  
  
            
  
            
            
    <title>Trials | Full text | Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial</title>
<link rel="shortcut icon" type="image/x-icon" href="/images/icon/10096/favicon.ico" />
<link rel="apple-touch-icon" sizes="72x72" href="/sites/10096/images/70.gif" />
<meta http-equiv="X-UA-Compatible" content="IE=7" />


                
    
		
		
		
		
<!-- <?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:cc="http://web.resource.org/cc/" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">
<cc:Work rdf:about="http://www.trialsjournal.com/content/16/1/24">
<cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
</cc:Work>
<cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
<cc:permits rdf:resource="http://web.resource.org/cc/Reproduction"/>
<cc:permits rdf:resource="http://web.resource.org/cc/Distribution"/>
<cc:requires rdf:resource="http://web.resource.org/cc/Notice"/>
<cc:requires rdf:resource="http://web.resource.org/cc/Attribution"/>
<cc:permits rdf:resource="http://web.resource.org/cc/DerivativeWorks"/>
</cc:License>
<item rdf:about="http://www.trialsjournal.com/content/16/1/24">
<title>Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial</title>
<dc:title>Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial</dc:title>
<dc:creator>Harris, Patrick NA</dc:creator>
<dc:creator>Peleg, Anton Y</dc:creator>
<dc:creator>Iredell, Jon</dc:creator>
<dc:creator>Ingram, Paul R</dc:creator>
<dc:creator>Miyakis, Spiros</dc:creator>
<dc:creator>Stewardson, Andrew J</dc:creator>
<dc:creator>Rogers, Benjamin A</dc:creator>
<dc:creator>McBryde, Emma S</dc:creator>
<dc:creator>Roberts, Jason A</dc:creator>
<dc:creator>Lipman, Jeff</dc:creator>
<dc:creator>Athan, Eugene</dc:creator>
<dc:creator>Paul, Sanjoy K</dc:creator>
<dc:creator>Baker, Peter</dc:creator>
<dc:creator>Harris-Brown, Tiffany</dc:creator>
<dc:creator>Paterson, David L</dc:creator>
<dc:identifier>info:doi/10.1186/s13063-014-0541-9</dc:identifier>
<dc:identifier>info:pmid/25623485</dc:identifier>
<dc:source>Trials 2015, 16:24</dc:source>
<dc:date>2015-01-27</dc:date>

<prism:publicationName>Trials</prism:publicationName>
<prism:publicationDate>2015-01-27</prism:publicationDate>
<prism:volume>16</prism:volume>
<prism:number>1</prism:number>
<prism:section>Study protocol</prism:section>
<prism:startingPage>24</prism:startingPage>
<prism:copyright>2015 Harris et al.; licensee BioMed Central.</prism:copyright>
</item>
</rdf:RDF>
 -->
 
 
<meta name="citation_journal_title" content="Trials" />
<meta name="citation_publisher" content="BioMed Central Ltd" />


<meta name="citation_author" content="Patrick NA Harris" />
<meta name="citation_author_institution" content="University of Queensland Centre for Clinical Research, Building 71/918 Royal Brisbane & Women’s Hospital Campus, Herston, Brisbane, 4029, QLD, Australia" />
<meta name="citation_author" content="Anton Y Peleg" />
<meta name="citation_author_institution" content="Department of Infectious Diseases, The Alfred Hospital, Melbourne, VIC, Australia" />
<meta name="citation_author" content="Jon Iredell" />
<meta name="citation_author_institution" content="Westmead Millenium Institute for Medical Research, Westmead Hospital, Sydney, NSW, Australia" />
<meta name="citation_author" content="Paul R Ingram" />
<meta name="citation_author_institution" content="Department of Microbiology and Infectious Diseases, Royal Perth Hospital, Perth, WA, Australia" />
<meta name="citation_author_institution" content="School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, WA, Australia" />
<meta name="citation_author" content="Spiros Miyakis" />
<meta name="citation_author_institution" content="Department of Infectious Diseases, School of Medicine, University of Wollongong and The Wollongong Hospital, Wollongong, NSW, Australia" />
<meta name="citation_author" content="Andrew J Stewardson" />
<meta name="citation_author_institution" content="Department of Infectious Diseases, Austin Health, Melbourne, VIC, Australia" />
<meta name="citation_author" content="Benjamin A Rogers" />
<meta name="citation_author_institution" content="Monash Infectious Disease, Monash Health, Clayton, VIC, Australia" />
<meta name="citation_author" content="Emma S McBryde" />
<meta name="citation_author_institution" content="Victorian Infectious Diseases Unit, Royal Melbourne Hospital, Melbourne, VIC, Australia" />
<meta name="citation_author" content="Jason A Roberts" />
<meta name="citation_author_institution" content="Burns Trauma and Critical Care Research Centre, The University of Queensland, Brisbane, QLD, Australia" />
<meta name="citation_author" content="Jeff Lipman" />
<meta name="citation_author_institution" content="Burns Trauma and Critical Care Research Centre, The University of Queensland, Brisbane, QLD, Australia" />
<meta name="citation_author" content="Eugene Athan" />
<meta name="citation_author_institution" content="Department of Infectious Disease, Barwon Health, Deakin University, Geelong, VIC, Australia" />
<meta name="citation_author" content="Sanjoy K Paul" />
<meta name="citation_author_institution" content="Clinical Trials & Biostatistics Unit, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia" />
<meta name="citation_author" content="Peter Baker" />
<meta name="citation_author_institution" content="Queensland Clinical Trials and Biostatistics Centre, University of Queensland, Brisbane, QLD, Australia" />
<meta name="citation_author" content="Tiffany Harris-Brown" />
<meta name="citation_author_institution" content="University of Queensland Centre for Clinical Research, Building 71/918 Royal Brisbane & Women’s Hospital Campus, Herston, Brisbane, 4029, QLD, Australia" />
<meta name="citation_author" content="David L Paterson" />
<meta name="citation_author_institution" content="University of Queensland Centre for Clinical Research, Building 71/918 Royal Brisbane & Women’s Hospital Campus, Herston, Brisbane, 4029, QLD, Australia" />


<meta name="citation_issn" content="1745-6215" />
<meta name="citation_title" content="Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial" />
<meta name="citation_volume" content="16" />
<meta name="citation_issue" content="1" />
<meta name="citation_date" content="2015-01-27" />
<meta name="citation_firstpage" content="24" />
<meta name="citation_doi" content="10.1186/s13063-014-0541-9" />
<meta name="citation_pdf_url" content="http://www.trialsjournal.com/content/pdf/s13063-014-0541-9.pdf" />
<meta name="citation_pmid" content="25623485" />
<link rel="alternate" type="application/pdf" title="PDF" href="http://www.trialsjournal.com/content/pdf/s13063-014-0541-9.pdf" />
<meta name="title" content="Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial" />
<meta name="description" content="Gram-negative bacteria such as Escherichia coli or Klebsiella spp. frequently cause bloodstream infections. There has been a worldwide increase in resistance in these species to antibiotics such as third generation cephalosporins, largely driven by the acquisition of extended-spectrum beta-lactamase or plasmid-mediated AmpC enzymes. Carbapenems have been considered the most effective therapy for serious infections caused by such resistant bacteria; however, increased use creates selection pressure for carbapenem resistance, an emerging threat arising predominantly from the dissemination of genes encoding carbapenemases. Recent retrospective data suggest that beta-lactam/beta-lactamase inhibitor combinations, such as piperacillin-tazobactam, may be non-inferior to carbapenems for the treatment of bloodstream infection caused by extended-spectrum beta-lactamase-producers, if susceptible in vitro. This study aims to test this hypothesis in an effort to define carbapenem-sparing alternatives for these infections." />

<meta name="dc.title" content="Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial" />
<meta name="dc.creator" content="Harris, Patrick NA" />
<meta name="dc.creator" content="Peleg, Anton Y" />
<meta name="dc.creator" content="Iredell, Jon" />
<meta name="dc.creator" content="Ingram, Paul R" />
<meta name="dc.creator" content="Miyakis, Spiros" />
<meta name="dc.creator" content="Stewardson, Andrew J" />
<meta name="dc.creator" content="Rogers, Benjamin A" />
<meta name="dc.creator" content="McBryde, Emma S" />
<meta name="dc.creator" content="Roberts, Jason A" />
<meta name="dc.creator" content="Lipman, Jeff" />
<meta name="dc.creator" content="Athan, Eugene" />
<meta name="dc.creator" content="Paul, Sanjoy K" />
<meta name="dc.creator" content="Baker, Peter" />
<meta name="dc.creator" content="Harris-Brown, Tiffany" />
<meta name="dc.creator" content="Paterson, David L" />
<meta name="dc.description" content="Gram-negative bacteria such as Escherichia coli or Klebsiella spp. frequently cause bloodstream infections. There has been a worldwide increase in resistance in these species to antibiotics such as third generation cephalosporins, largely driven by the acquisition of extended-spectrum beta-lactamase or plasmid-mediated AmpC enzymes. Carbapenems have been considered the most effective therapy for serious infections caused by such resistant bacteria; however, increased use creates selection pressure for carbapenem resistance, an emerging threat arising predominantly from the dissemination of genes encoding carbapenemases. Recent retrospective data suggest that beta-lactam/beta-lactamase inhibitor combinations, such as piperacillin-tazobactam, may be non-inferior to carbapenems for the treatment of bloodstream infection caused by extended-spectrum beta-lactamase-producers, if susceptible in vitro. This study aims to test this hypothesis in an effort to define carbapenem-sparing alternatives for these infections." />
<meta name="dc.source" content="Trials 2015 16:24" />
<meta name="dc.format" content="text/html" />
<meta name="dc.publisher" content="BioMed Central Ltd" />
<meta name="dc.date" content="2015-01-27" />
<meta name="dc.type" content="Study protocol" />
<meta name="dc.identifier" content="10.1186/s13063-014-0541-9" />
<meta name="dc.identifier" content="info:pmid/25623485" />
<meta name="dc.language" content="en" />
<meta name="dc.copyright" content="2015 Harris et al.; licensee BioMed Central." />
<meta name="dc.rights" content="http://creativecommons.org/licenses/by/2.0/" />
<meta name="dc.rightsAgent" content="reprints@biomedcentral.com" />

<meta name="prism.issn" content="1745-6215" />
<meta name="prism.publicationName" content="Trials" />
<meta name="prism.publicationDate" content="2015-01-27" />
<meta name="prism.volume" content="16" />
<meta name="prism.number" content="1" />
<meta name="prism.section" content="Study protocol" />
<meta name="prism.startingPage" content="24" />
<meta name="prism.copyright" content="2015 Harris et al.; licensee BioMed Central." />
<meta name="prism.rightsAgent" content="reprints@biomedcentral.com" />


        <meta name="citation_abstract_html_url" content="http://www.trialsjournal.com/content/16/1/24/abstract" />
            <meta name="citation_fulltext_html_url" content="http://www.trialsjournal.com/content/16/1/24" />
            <link rel='alternate' type='text/xml' title='XML version' href='http://www.trialsjournal.com/content/download/xml/s13063-014-0541-9.xml' />
            <link rel="image_src" href="http://www.trialsjournal.com/content/figures/s13063-014-0541-9-toc.gif" />
    
     <link rel="section" href="http://trialsjournal.com/content/download/supplementary/s13063-014-0541-9-s1.docx" title="Additional file 1:" /> <link rel="section" href="http://trialsjournal.com/content/download/supplementary/s13063-014-0541-9-s2.docx" title="Additional file 2:" />
    
    
                    
    

<script type="text/javascript">
// must run before css
document.documentElement.id = "js";
</script>



						
   
  
      
  
                  
  
                  
  
            
  
            
            



						
        <script type="text/javascript" src="http://www.bmcimg.com/javascript/plugins/jquery-1.8.2.min-0.js"></script>

	                <link rel="stylesheet" type="text/css" href="/css/main-0.css" media="screen, print"/>
    
                <link rel="stylesheet" type="text/css" href="/css/plugins-0.css" media="screen, print"/>
    



    

			                <link rel="stylesheet" type="text/css" href="http://www.bmcimg.com/css/articles-0.css" media="screen, print"/>
    	

    

    <link rel="stylesheet" type="text/css" href="/css/themes/10096.css" media="screen, print"/>


                <link rel="stylesheet" type="text/css" href="/css/media/print-0.css" media="print"/>
    



<!--[if IE]>
                    <link rel="stylesheet" type="text/css" href="/css/hacks/ie-0.css"/>
    <![endif]-->

<!--[if IE 7]>
                    <link rel="stylesheet" type="text/css" href="/css/hacks/ie7-0.css"/>
    <![endif]-->
			
<script type="text/javascript">
    //configuration
    OAS_url = '//oas.biomedcentral.com/RealMedia/ads/';

	// control of advert's position on page [AMC]
    
    	
	
    OAS_sitepage = "trialsjournal.com/article/10.1186/s13063/014/0541/9";
    	
		OAS_listpos = 'Top,x96,Right3';
	
	
			
		OAS_query = '';
		
	

    OAS_target = '_top';
    //end of configuration
    OAS_version = 10;
    OAS_rn = '001234567890'; OAS_rns = '1234567890';
    OAS_rn = new String (Math.random()); OAS_rns = OAS_rn.substring (2, 11);
    function OAS_NORMAL(pos) {
		document.write('<a href="' + OAS_url + 'click_nx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '!' + pos + '?' + OAS_query + '" target="' + OAS_target + '">');
		document.write('<img src="' + OAS_url + 'adstream_nx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '!' + pos + '?' + OAS_query + '" border="0"/></a>');
    }
    
	function refererTerms(referer) {

	if(referer.match("q=") != null) {
		referer = referer.split("q=");
		referer = referer[1].split("&");
		referer = referer[0];
	} else {
		referer = referer;
	}

		if(referer.match("%20") != null && referer.match("%20").length >= 1) {
			referer =  referer.replace(/%20/gi,"+");
			return referer;
		} else { 
			return referer; 
		}
	}
 </script>


 <script type="text/javascript">
	// Set the version of JavaScript to 10 for a Browser 'Mozilla/3' on webTV 
    OAS_version = 11;
    if ((navigator.userAgent.indexOf('Mozilla/3') != -1) || (navigator.userAgent.indexOf('Mozilla/4.0 WebTV') != -1)) {
     OAS_version = 10; }
    if (OAS_version >= 11) {
    document.write('<scr' + 'ipt type="text/javascript" src="' + OAS_url + 'adstream_mjx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '?' + OAS_query + '"><\/script>'); }
</script>
	
<script type="text/javascript">
    document.write('');
	
    function OAS_AD(pos) {
        if (OAS_version >= 11)
         OAS_RICH(pos);
        else
         OAS_NORMAL(pos);
    }
 </script>
	





<script type="text/javascript">
    jsonLoaders = function(){
        var _loaders = [];
        return {
            register: function(config){
                config.prefix = config.prefix || '/webapi/1.0/blogs/';
                config.feedLength = config.feedLength || 3;

                _loaders.push(config);
            },
            list: function(){return _loaders}
        };
    }();

    function totext() {
	    document.write('<a href="javascript:returnToText();">Return to text</a>');
    }

    function retrieve_doi(){
        var metas = document.getElementsByTagName('meta');
        var i;
        for (i = 0; i < metas.length; i++)
            if (metas[i].getAttribute('name') == "citation_doi")
                break;
        var citation_doi = metas[i].getAttribute('content');
        return citation_doi;
    }

</script>





    <script src="http://tjs.sjs.sinajs.cn/open/api/js/wb.js" type="text/javascript" charset="utf-8"></script>
        <link title="Latest articles" rel="alternate" href="http://www.trialsjournal.com/latest/rss" type="application/rss+xml" exposeToHeader="true"/>
    <link title="Most viewed" rel="alternate" href="http://www.trialsjournal.com/mostviewed/rss/" type="application/rss+xml" exposeToHeader="true"/>
    <link title="Latest comments" rel="alternate" href="http://www.trialsjournal.com/latestcomments/rss" type="application/rss+xml" exposeToHeader="true"/>
    


	<script type="text/javascript">
	var _gaq = _gaq || [];
	_gaq.push(['_setAccount', 'UA-9663741-5']);
	_gaq.push(['_gat._anonymizeIp']);
	_gaq.push(['_setLocalRemoteServerMode']);
	
	/*for cross domain tracking*/
	//_gaq.push(['_setAllowLinker', true]);
    //_gaq.push(['_setDomainName', 'trialsjournal.com']); //this journal's domain
	/**/
	
		_gaq.push(['_trackPageview']); 

	(function() {
		var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
		ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
		var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);

		//var iframe = document.getElementById('casesdb-search-widget');
		//if(iframe !== null) {
		//	var pageTracker = _gat._getTrackerByName();
		//	iframe.src = pageTracker._getLinkerUrl('http://www.casesdatabase.com/');
		//}
	})();
	</script>

	
        </head>


<body class=" theme    ">


        



   
  
      
  
                  
  
                  
  
            
  
            
            

    

<div id="oas-campaign" style="display:none">trialsjournal.com/article/10.1186/s13063/014/0541/9</div>
<div id="oas-positions" style="display:none">Bottom,Top</div>

<div id="branding" role="banner">
                			
		<dl class="google-ad wide ">
	<dt class="hide">
					<a class="banner-ad" href="http://www.biomedcentral.com/advertisers/digital_advertising"></a>
				
			</dt>
		<dd>

		<!-- OAS AD 'Top' begin -->
		<script type="text/javascript">
		OAS_AD('Top');

		</script>
		<!-- OAS AD 'Top' end -->
		</dd>

		</dl>

		<noscript>
			<dl class="google-ad wide noscript">  
    <dt class="hide"></dt>
    
    <dd>
        <a href="//oas.biomedcentral.com/RealMedia/ads/click_nx.ads/trialsjournal.com/article/10.1186/s13063/014/0541/9/12091130812@Top?">
            <img src="//oas.biomedcentral.com/RealMedia/ads/adstream_nx.ads/trialsjournal.com/article/10.1186/s13063/014/0541/9/12846779210@Top?" alt="advert"/>
        </a>
    </dd>
			</dl>
		</noscript>
			            <div class="sup-panel-outer">
        <div class="sup-panel-inner">

            <style>
  #nojs li.greeting, #nojs li#loginLink {display:none;}
</style>


<ul id="login" class="login">

    <noscript><li><a href="/log"><img class="greeting" src="/images/log.gif"/></a></li></noscript>
    
    <li id="welcome"><span id="username"></span></li>

    <li id="loginLink"><a href=""></a></li>
    
    
</ul>

<script>

function login() {

/* cookie getter/setter */
var allCookies = {
  getItem: function (sKey) {
    if (!sKey || !this.hasItem(sKey)) { return null; }
    return unescape(document.cookie.replace(new RegExp("(?:^|.*;\\s*)" + escape(sKey).replace(/[\-\.\+\*]/g, "\\$&") + "\\s*\\=\\s*((?:[^;](?!;))*[^;]?).*"), "$1"));
  },
  setItem: function (sKey, sValue, vEnd, sPath, sDomain, bSecure) {
    if (!sKey || /^(?:expires|max\-age|path|domain|secure)$/i.test(sKey)) { return; }
    var sExpires = "";
    if (vEnd) {
      switch (vEnd.constructor) {
        case Number:
          sExpires = vEnd === Infinity ? "; expires=Tue, 19 Jan 2038 03:14:07 GMT" : "; max-age=" + vEnd;
          break;
        case String:
          sExpires = "; expires=" + vEnd;
          break;
        case Date:
          sExpires = "; expires=" + vEnd.toGMTString();
          break;
      }
    }
    document.cookie = escape(sKey) + "=" + escape(sValue) + sExpires + (sDomain ? "; domain=" + sDomain : "") + (sPath ? "; path=" + sPath : "") + (bSecure ? "; secure" : "");
  },
  removeItem: function (sKey, sPath) {
    if (!sKey || !this.hasItem(sKey)) { return; }
    document.cookie = escape(sKey) + "=; expires=Thu, 01 Jan 1970 00:00:00 GMT" + (sPath ? "; path=" + sPath : "");
  },
  hasItem: function (sKey) {
    return (new RegExp("(?:^|;\\s*)" + escape(sKey).replace(/[\-\.\+\*]/g, "\\$&") + "\\s*\\=")).test(document.cookie);
  },
  keys: /* optional method: you can safely remove it! */ function () {
    var aKeys = document.cookie.replace(/((?:^|\s*;)[^\=]+)(?=;|$)|^\s*|\s*(?:\=[^;]*)?(?:\1|$)/g, "").split(/\s*(?:\=[^;]*)?;\s*/);
    for (var nIdx = 0; nIdx < aKeys.length; nIdx++) { aKeys[nIdx] = unescape(aKeys[nIdx]); }
    return aKeys;
  }
};

// converts cookie into js object
function parseCookie(cookie) {

    cookie = cookie.split("&");
    var obj = {};

    for(var i = 0; i < cookie.length; i++) {

        var c = cookie[i].split("=");

        c[0] = c[0].replace('"','');
        
        obj[c[0]] = c[1];

    }
    return obj;
}

    var cookie = allCookies.getItem("bmccookie");

    var obj = (cookie != null) ? parseCookie(cookie) : {};
    

        var welcome = "";

        if(obj.hasOwnProperty("fname")) {

            // insert user welcome
            welcome = obj.fname.replace(/\+/g, " ") + " " + obj['lname'].replace(/\+/g," ");

            if(jQuery("#welcome").length > 0) {
              jQuery("#welcome").prepend("<strong>Welcome</strong> ");
              jQuery("#username").prepend('<strong>' + welcome + '</strong><span class="divider"></span>');
            } 

            // update link url
            jQuery("#loginLink a").text("Log off");
            jQuery("#loginLink a").attr("href", window.location.protocol + "//" + window.location.host + "/logoff");

            window.bmcloggedon = true;


        } else if(obj.hasOwnProperty("institution_name")) {

            // insert institution name
            welcome = obj["institution_name"].replace(/\+/g," ");
            
            if(jQuery("#welcome").length > 0) { 
                jQuery("#welcome").prepend("<strong>Welcome</strong> ");
                jQuery("#username").prepend('<strong>' + welcome + '</strong><span class="divider"></span>');
            } 

            // update link url
            jQuery("#loginLink a").text("Log on");
            jQuery("#loginLink a").attr("href", window.location.protocol + "//" + window.location.host + "/logon");

            window.bmcloggedon = false;


        } else {
            jQuery("#welcome").innerHTML = "";
            jQuery("#loginLink a").text("Log on");
            jQuery("#loginLink a").attr("href", window.location.protocol + "//" + window.location.host + "/logon");

            window.bmcloggedon = false;

        }


        // if athens login cookie doesn't exist and the athens login link is visible then remove it.
        if(allCookies.hasItem("athens") != true && document.getElementById("loginAthensLink") != null) {
          jQuery("#loginAthensLink").hide();
        }

}

login();


</script>

            <ul class="nav-sup">

    
        <li id="BMC" class="current">
            <a href="http://www.biomedcentral.com/"><span class="img-title">&nbsp;</span>
            <span class="text-title">BioMed Central</span></a>
        </li>
		
        		<li><a href="http://www.biomedcentral.com/journals"><span>Journals</span></a></li>
		
								<li>
				<a href="http://www.biomedcentral.com/gateways"><span>Gateways</span></a>
			</li>
					    	
</ul>
        </div>
    </div>
    <div class="branding-inner">

        

    
<style>
.survey {
	margin: 10px 0;
}
.survey, .survey .survey-sentence {
	font-size: 13px;
}
.survey-button a, .survey-button a:active, .survey-button a:visited, .survey-button a:hover  {
    color: #FFFFFF;
    text-decoration: none;
}
.survey-button {
	background-color: #FFA500;
    border-radius: 5px;
    color: #FFFFFF;
    font-weight: bold;
    font-size: 13px;
    font-weight: bold;
    padding: 5px 13px;
    background: #ef8142; /* Old browsers */
	background: -moz-linear-gradient(top,  #ef8142 0%, #ef8142 50%, #a64510 100%, #a64510 100%); /* FF3.6+ */
	background: -webkit-gradient(linear, left top, left bottom, color-stop(0%,#ef8142), color-stop(50%,#ef8142), color-stop(100%,#a64510), color-stop(100%,#a64510)); /* Chrome,Safari4+ */
	background: -webkit-linear-gradient(top,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* Chrome10+,Safari5.1+ */
	background: -o-linear-gradient(top,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* Opera 11.10+ */
	background: -ms-linear-gradient(top,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* IE10+ */
	background: linear-gradient(to bottom,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* W3C */
	filter: progid:DXImageTransform.Microsoft.gradient( startColorstr='#ef8142', endColorstr='#a64510',GradientType=0 ); /* IE6-9 */

}
</style>




          <div class="logo">
        <a href="/"><img alt="Trials" title="Trials Logo" src="/sites/10096/images/logo.gif" /></a>     
      </div>    
        
                    



            <div id="impact-factor" class="official">
    <img src="/images/branding/official.gif" alt="official impact factor" title="2.12"/>
    <span id="impact-factor-value">2.12</span>
</div>
    
                            

<div class="module search gray small  " role="search">
    <div class="module-inner padded">
        <form method="get" class="searchForm"
              action=" /quickSearchRedirectURL "
              onsubmit="window.location.href=this['url'].value + '?terms=' + encodeURIComponent(this['terms'].value); return false;">
            <fieldset class="search">
			                <span>
                    Search <select name="url">
                                <option value="http://www.trialsjournal.com/search/results" selected>Trials</option>
                                <option value="http://www.biomedcentral.com/search/results">BioMed Central</option>
                           </select> for
                </span>
                            <input id="searchTerms" name="terms" type="text" alt="Search terms" class="text " />
                 <button class="w37" value="Go" type="submit">Go</button>
            </fieldset>
        </form>
    </div>
	<a class="advanced-search" href="/search">Advanced search</a>
</div> 

                        <div id="mobile-nav-list" >

	<ul class="primary-nav" role="navigation">
		<li     ><a href="/"><span id="home-tab">Home</span></a></li>
														<li             class="current"
    ><a href="/content"><span id="articles-tab">Articles</span></a></li>
										
	

	
            <li     ><a href="/authors/instructions"><span id="authors-tab">Authors</span></a></li>
        <li     ><a href="/about/reviewers"><span id="reviewers-tab">Reviewers</span></a></li>
    		<li     ><a href="/about"><span id='about-tab'>About this journal</span></a></li>
	<li     ><a href="/my"><span id="my-tab">My Trials</span></a></li>
		
    		</ul>
</div>
            </div>
</div>

<hr class="hide" />
<div class="container">
	<div id="content"  class="overflow-visible"  role="main">
			    
	

<!--div class="branding-mobile">
		<h1 class="logo">
	    <a href="/">
		    <img alt="Trials" title="Trials Logo" src="/sites/10096/images/logo.gif" />
		</a>
		</h1>
	</div><br/-->



			
	



<div class="outline-wrapper block mobile-hidden" id="left-article-box">
<ul id="box-outline" class="box">
<ul id="outline" class="outline">
   <li>
      <a href="#">Top</a>
   </li>
   <li>
      <a href="#abs">Abstract</a>
   </li>
   <li>
      <a href="#sec1">Background</a>
   </li>
   <li>
      <a href="#sec2">Methods/Design</a>
   </li>
   <li>
      <a href="#sec3">Discussion</a>
   </li>
   <li>
      <a href="#sec4">Trial status</a>
   </li>
   <li>
      <a href="#sec5">Abbreviations</a>
   </li>
   <li>
      <a href="#sec6">Competing interests</a>
   </li>
   <li>
      <a href="#sec7">Authors’ contributions</a>
   </li>
   <li class="long">
      <a href="#sec8" class="clipped" onmouseover="outlineover(this)" onmouseout="outlineout(this)" title="Authors’ information">Authors’ info...</a>
   </li>
   <li class="long">
      <a href="#sec9" class="clipped" onmouseover="outlineover(this)" onmouseout="outlineout(this)" title="Additional files">Additional fi...</a>
   </li>
   <li>
      <a href="#ack">Acknowledgments</a>
   </li>
   <li class="lowest">
      <a href="#refs">References</a>
   </li>
</ul>
</ul>

<dl id="box-outline1">
</dl>

				



</div>



<div class="mobile-hidden" id="right-panel">
 	
<div id="mobile-sidebar">
	<div id="mobile-sidebar-tab">
		<span>
			<a href="#" id="mobile-sidebar-tab-link"><img src="/images/sidebar-hidden.png"><img style="display:none;" src="/images/sidebar-shown.png"></a>
		</span>
	</div>	<div id="mobile-sidebar-list">

<div id="article-navigation-bar">
    <div class="issue-information block">
        <h5><a href="http://www.trialsjournal.com"><strong>Trials</strong></a></h5>
 		        <ul class="square normal">
            <li><a href="http://www.trialsjournal.com/content/16">Volume 16</a></li>
				
                    </ul>
    </div>

    <div class="article-information block" id="article-info">
        


<div id="viewing-options-links">
	<h5>Viewing options</h5>
	<ul class="square normal">
        
            <li>
                             <a onclick="_gaq.push(['_trackEvent', 'Abstract', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="/content/16/1/24/abstract">Abstract</a>
                        </li>
        				<li>
							<strong>Full text</strong>
					</li>
				
		<li class="pdfFileSize">
			<a onclick="_gaq.push(['_trackEvent', 'PDF download', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="/content/pdf/s13063-014-0541-9.pdf">PDF</a>
			<span>(600KB)</span>
		</li>

        
				<li>
						<a onclick="_gaq.push(['_trackEvent', 'additional files', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="/content/16/1/24/additional">Additional files</a>
					</li>
			</ul>

        
</div>
		
<div id="associated-material-links">
    <h5>Associated material</h5>
    <ul class="square normal">
                        <li>
            <a onclick="_gaq.push(['_trackEvent', 'Pubmed record', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="/pubmed/25623485">PubMed record</a>
        </li>
                            <li><a onclick="_gaq.push(['_trackEvent', 'Article metrics', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="/content/16/1/24/about">Article metrics</a></li>
                <li>
                        <a onclick="_gaq.push(['_trackEvent', 'Readers comments', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="/content/16/1/24/comments">Readers' comments </a>
                    </li>
        <li>
                            <a onclick="_gaq.push(['_trackEvent', 'Pre-publication history', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="/content/16/1/24/prepub">Pre-publication history</a>                    </li>
    </ul>
</div>
		




<div id="related-literature-links">
    <h5>Related literature</h5>
    <ul class="normal">
                    <li><a onclick="_gaq.push(['_trackEvent', 'Citied by', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="http://www.trialsjournal.com/content/16/1/24/about#citations">Cited by</a></li>
                <li id="google-blog-search"><a onclick="_gaq.push(['_trackEvent', 'Google blog search', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="http://www.google.com/search?tbm=blg&hl=en&amp;source=hp&amp;biw=1280&amp;bih=899&amp;q=%22Meropenem+versus+piperacillin-tazobactam+for+definitive+treatment+of+bloodstream+infections+due+to+ceftriaxone+non-susceptible+Escherichia+coli+and+Klebsiella+spp+%28the+MERINO+trial%29%3A+study+protocol+for+a+randomised+controlled+trial%22&amp;btnG=Search">Google blog search</a></li>
        <h6>Other articles by authors</h6>
        <li>
            <a class="collapser"><i>&nbsp;</i>on Google Scholar</a>
<ul id="authg" class="hidebeforeload">                         <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22PNA+Harris%22">Harris PNA</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22AY+Peleg%22">Peleg AY</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22J+Iredell%22">Iredell J</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22PR+Ingram%22">Ingram PR</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22S+Miyakis%22">Miyakis S</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22AJ+Stewardson%22">Stewardson AJ</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22BA+Rogers%22">Rogers BA</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22ES+McBryde%22">McBryde ES</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22JA+Roberts%22">Roberts JA</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22J+Lipman%22">Lipman J</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22E+Athan%22">Athan E</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22SK+Paul%22">Paul SK</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22P+Baker%22">Baker P</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22T+Harris-Brown%22">Harris-Brown T</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22DL+Paterson%22">Paterson DL</a>
            </li>
            </ul>          </li>
                <li>
            		<a class="collapser"><i>&nbsp;</i>on PubMed</a>
	<ul id="authpm" class="hidebeforeload"> 									<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Harris_PNA%20[Author]">Harris PNA</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Peleg_AY%20[Author]">Peleg AY</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Iredell_J%20[Author]">Iredell J</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Ingram_PR%20[Author]">Ingram PR</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Miyakis_S%20[Author]">Miyakis S</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Stewardson_AJ%20[Author]">Stewardson AJ</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Rogers_BA%20[Author]">Rogers BA</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=McBryde_ES%20[Author]">McBryde ES</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Roberts_JA%20[Author]">Roberts JA</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Lipman_J%20[Author]">Lipman J</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Athan_E%20[Author]">Athan E</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Paul_SK%20[Author]">Paul SK</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Baker_P%20[Author]">Baker P</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Harris-Brown_T%20[Author]">Harris-Brown T</a>
				</li>
												<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Paterson_DL%20[Author]">Paterson DL</a>
				</li>
						</ul > 	        </li>
    </ul>     <h6>Related articles/pages</h6>
    <ul class="square normal">
        <li><a onclick="_gaq.push(['_trackEvent', 'on google', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="http://www.google.co.uk/search?hl=en&amp;q=related:http://www.trialsjournal.com/content/16/1/24">on Google</a></li>
        <li><a onclick="_gaq.push(['_trackEvent', 'on google scholar', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="http://scholar.google.com/scholar?q=related:http://www.trialsjournal.com/content/16/1/24">on Google Scholar</a></li>
                    <li><a onclick="_gaq.push(['_trackEvent', 'on Pubmed', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="/pubmed/related/25623485">on PubMed</a></li>
            </ul>

</div>		
        
    
    
        

    	






<h5>Tools</h5>
	<ul class="square normal">
									<li>
						<a onclick="_gaq.push(['_trackEvent', 'download references', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="/content/16/1/24/citation">Download references</a>
					</li>
				<li><a onclick="_gaq.push(['_trackEvent', 'download xml', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="/content/download/xml/s13063-014-0541-9.xml">Download XML</a></li>
				<li>
						<a onclick="_gaq.push(['_trackEvent', 'email2friend', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="/content/16/1/24/email">Email to a friend</a>
					</li>
		<li><a onclick="_gaq.push(['_trackEvent', 'order reprints', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="https://www.odysseypress.com/onlinehost/reprint_order.php?type=A&page=0&journal=738&doi=10.1186/s13063-014-0541-9&volume=16&issue=1&title=Meropenem+versus+piperacillin-tazobactam+for+definitive+treatment+of+bloodstream+infections+due+to+ceftriaxone+non-susceptible+Escherichia+coli+and+Klebsiella+spp+%28the+MERINO+trial%29%3A+study+protocol+for+a+randomised+controlled+trial&author_name=Patrick NA Harris&start_page=1&end_page=8">Order reprints</a></li>
		<li>
						<a onclick="_gaq.push(['_trackEvent', 'post a comment', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="/content/16/1/24/postcomment">Post a comment</a>
					</li>			
		<ul id="download-to-links">
			<a class="downloadto_title btn" href="#"><span class="icon">&nbsp;</span>Download to ...</a>
			
			<ul id="downloadto" class="iconlist hidebeforeload" style="display: none;">
				<li>
					<a href="http://redirect.papersapp.com/redirect?url=http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F24" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Papers', 'Article Sidebar', '/content/16/1/24', 1, true]);"><span class="share-icons papers"></span>Papers</a>
				</li>
				<li>
					<a href="http://www.mendeley.com/import/?url=http://www.trialsjournal.com/content/16/1/24" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Mandeley', 'Article Sidebar', '/content/16/1/24', 1, true]);"><span class="share-icons mendeley"></span>Mendeley</a>
				</li>
			</ul>
		</ul>
		
		<ul id="mobile-downloadto" class="iconlist">
		
		<h6>Download to ...</h6>
			<li>
				<a href="http://redirect.papersapp.com/redirect?url=http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F24" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Papers', 'Article Sidebar', '/content/16/1/24', 1, true]);"><span class="share-icons papers"></span>Papers</a>
			</li>
			
			<li>
				<a href="http://www.mendeley.com/import/?url=http://www.trialsjournal.com/content/16/1/24" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Mandeley', 'Article Sidebar', '/content/16/1/24', 1, true]);"><span class="share-icons mendeley"></span>Mendeley</a>
			</li>
		</ul>

		
	</ul>
		




<h5>Share this article</h5>
<ul id="social-networking-links">
	<li>
	<div class="fb-like" onclick="_gaq.push(['_trackEvent', 'Facebook Recommend', 'Article Sidebar', '/content/16/1/24', 1, true]);" data-href="http://www.trialsjournal.com/content/16/1/24" data-send="false" data-layout="button_count" data-width="100" data-show-faces="false" data-action="recommend"></div>
	</li>
	<li>
		<a onclick="_gaq.push(['_trackEvent', 'Share Twitter Recommend', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="http://twitter.com/share" data-url="http://www.trialsjournal.com/content/16/1/24" data-counturl="http://www.trialsjournal.com/content/16/1/24" data-hashtags="trials
" data-text="Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial" class="twitter-share-button">Tweet</a>
	</li>
	<li>
			<g:plusone size="medium" width="100"></g:plusone>
	</li>

        <li>
        <wb:share-button onclick="_gaq.push(['_trackEvent', 'Recommend Google plus', 'Article Sidebar', '/content/16/1/24', 1, true]);" addition="number" type="button" ralateUid="2216240737" title="Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial http://www.trialsjournal.com/content/16/1/24"></wb:share-button>
    </li>
    
		<a class="sharethis_title btn" href="#"><span class="icon">&nbsp;</span>More options...</a>
	<ul class="iconlist hidebeforeload" id="sharethis">
			<li>
				<a target="_blank" onclick="_gaq.push(['_trackEvent', 'citeu Like', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="http://www.citeulike.org/posturl?url=http://www.trialsjournal.com/content/16/1/24"><span class="share-icons citeulike"></span>Citeulike</a>
			</li>
				<li>
			<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share Linkedin', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="http://www.linkedin.com/shareArticle?mini=true&url=%26%2335%3Btrials%0D%0AMeropenem%20versus%20piperacillin-tazobactam%20for%20definitive%20treatment%20of%20bloodstream%20infections%20due%20to%20ceftriaxone%20non-susceptible%20Escherichia%20coli%20and%20Klebsiella%20spp%20%28the%20MERINO%20trial%29%3A%20study%20protocol%20for%20a%20randomised%20controlled%20trial%20http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F24&title=Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial"><span class="share-icons linkedin"></span>LinkedIn</a>
	</li>
			<li>
				<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share delicious', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="http://del.icio.us/post?url=http://www.trialsjournal.com/content/16/1/24&title=Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial"><span class="share-icons delicious"></span>Del.icio.us</a>
	</li>
			<li>
				<a onclick="_gaq.push(['_trackEvent', 'Share via email', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="/content/16/1/24/email"><span class="share-icons email"></span>Email</a>
	</li>
			<li>
				<a onclick="target="_blank" onclick="_gaq.push(['_trackEvent', 'Share facebook', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="http://www.facebook.com/sharer.php?u=http://www.trialsjournal.com/content/16/1/24"><span class="share-icons facebook"></span>Facebook</a>
	</li>
	<li class="gp">
			<div class="googlehider mobile-hide"> 
				<div class="g-plusone" data-annotation="none"></div>
			</div>
				<span class="share-icons googleplus mobile-hide"></span>
				<div class="googlehider2 mobile-hide"> 
				<div class="g-plusone mobile-hide" data-annotation="none"></div>
			</div>
				<span class="share-icons googleplus"></span>
				<span class="gp-link"><a  onclick="_gaq.push(['_trackEvent', 'Share google plus', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="#">Google+</a></span>
	</li>
			<li>
				<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share Mandeley', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="http://www.mendeley.com/import/?url=http://www.trialsjournal.com/content/16/1/24"><span class="share-icons mendeley"></span>Mendeley</a>
			</li>
			<li>
			<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share twitter icon', 'Article Sidebar', '/content/16/1/24', 1, true]);" href="http://twitter.com/?status=Meropenem%20versus%20piperacillin-tazobactam%20for%20definitive%20treatment%20of%20bloodstream%20infections%20due%20to%20ceftriaxone%20non-susceptible%20Escherichia%20coli%20and%20Klebsiella%20spp%20%28the%20MERINO%20trial%29%3A%20study%20protocol%20for%20a%20randomised%20controlled%20trial%20http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F24+%23trials
"><span class="share-icons twitter"></span>Twitter</a>
			</li>

			<li><a href="http://www.reddit.com/submit" onclick="window.location = 'http://www.reddit.com/submit?url=http://www.trialsjournal.com/content/16/1/24'; return false"> <span class="share-icons reddit"></span>Reddit</a>
    </li>






		</ul>
</ul>

    </div>

    
  
        
                
        


















                                                                                
	

	    
   
  
      
  
                  
  
                  
  
            
  
            
            

<div id="signup-to-etoc" class="button-collection-margins block mobile-border-bottom">	
					<h3>Email updates</h3>
			<p id="receive_issue_alerts_journal_updates_text">Keep up to date with the latest news and content from Trials and BioMed Central.</p>
			
				
<form  id="articleSignupForUpdates"  method="post" action="/signuptoupdates.html">
	<div id="message-box"></div>
    <fieldset class="block-form">
        <input type="text" name="emailAddress" onblur="javascript: if (this.value == '') { this.value = 'email address'; }" onfocus="javascript: if (this.value == 'email address') { this.value = ''; }" value="email address"  class="text " id="email" />
        <input value="" type="hidden" name="returnUrl" id="returnUrl" />
        <input value="xniche-trials" type="hidden" name="listName" id="listName" />
        <input value="Trials" type="hidden" name="journalName" id="journalName" />
        <button onclick="_gaq.push('_trackEvent', 'Signup', 'Signup for Email updates', "Trials");" class="w74 right" type="submit" onmouseover="this.className='w74 hover right'" onmouseout="this.className='w74 right'" value="Sign up">Sign up</button>
    </fieldset>
</form>	
</div>

	


			<div id="advert-offset">
    					
		<dl class="google-ad  ">
	<dt class="hide">
				
					<a class="skyscraper-ad" href="http://www.biomedcentral.com/advertisers/digital_advertising">Advertisement</a>
			</dt>
		<dd>

		<!-- OAS AD 'Right3' begin -->
		<script type="text/javascript">
		OAS_AD('Right3');

		</script>
		<!-- OAS AD 'Right3' end -->
		</dd>

		</dl>

		<noscript>
			<dl class="google-ad  noscript">  
    <dt class="hide"><a href="http://www.biomedcentral.com/advertisers/digital_advertising">Advertisement</dt>
    
    <dd>
        <a href="//oas.biomedcentral.com/RealMedia/ads/click_nx.ads/trialsjournal.com/article/10.1186/s13063/014/0541/9/16968492311@Right3?">
            <img src="//oas.biomedcentral.com/RealMedia/ads/adstream_nx.ads/trialsjournal.com/article/10.1186/s13063/014/0541/9/16958053043@Right3?" alt="advert"/>
        </a>
    </dd>
			</dl>
		</noscript>
					</div>
	

	
</div>
		<div class="mobile-sidebar-gradient top"></div>
		<div class="mobile-sidebar-gradient bottom"></div>
	</div>

</div>








 </div>
<div class="rounded custom white article full-text">
<div class="wrap-inner content">
    <div class="padded-inner">            


    
   
  
      
  
                  
  
                  
  
            
  
            
            

<div id="topmatter">
	


	   






 
  



				<a href="/about/access"><img alt="Open Access" src="/images/articles/openaccess-large.png" class="access mr15"/></a>
					<span class="articletype">Study protocol</span>

<h1>Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible <em>Escherichia coli</em> and <em>Klebsiella</em> spp (the MERINO trial): study protocol for a randomised controlled trial</h1>
        
			<div class="multipleins">
		
	<p class="authors">
        																																																																																																																																																																																																																																																																																																																																																																																																																																																																																												         <strong>Patrick NA Harris</strong><sup><a href="/content/16/1/24/#ins1">1</a></sup><sup>&#42;</sup>, <strong>Anton Y Peleg</strong><sup><a href="/content/16/1/24/#ins2">2</a></sup>, <strong>Jon Iredell</strong><sup><a href="/content/16/1/24/#ins3">3</a></sup>, <strong>Paul R Ingram</strong><sup><a href="/content/16/1/24/#ins4">4</a></sup><sup><a href="/content/16/1/24/#ins5">5</a></sup>, <strong>Spiros Miyakis</strong><sup><a href="/content/16/1/24/#ins6">6</a></sup>, <strong>Andrew J Stewardson</strong><sup><a href="/content/16/1/24/#ins7">7</a></sup>, <strong>Benjamin A Rogers</strong><sup><a href="/content/16/1/24/#ins8">8</a></sup>, <strong>Emma S McBryde</strong><sup><a href="/content/16/1/24/#ins9">9</a></sup>, <strong>Jason A Roberts</strong><sup><a href="/content/16/1/24/#ins10">10</a></sup>, <strong>Jeff Lipman</strong><sup><a href="/content/16/1/24/#ins10">10</a></sup>, <strong>Eugene Athan</strong><sup><a href="/content/16/1/24/#ins11">11</a></sup>, <strong>Sanjoy K Paul</strong><sup><a href="/content/16/1/24/#ins12">12</a></sup>, <strong>Peter Baker</strong><sup><a href="/content/16/1/24/#ins13">13</a></sup>, <strong>Tiffany Harris-Brown</strong><sup><a href="/content/16/1/24/#ins1">1</a></sup> and <strong>David L Paterson</strong><sup><a href="/content/16/1/24/#ins1">1</a></sup>	</p>
	
				<div id="affiliations">
		<div class="module gray  inner">
<div class="module-inner padded-inner">
		<ul>
			<li>                        
                                                                                                                                                                                                    		<p class="authors" >
							<span>*</span>
									 Corresponding author:										            Patrick NA Harris <a href='mailto:p.harris@uq.edu.au'>p.harris@uq.edu.au</a>    					</p>
      
</li>
			
                                                                                                                                                                                                                                                                                                                                                                                                                                                    		</ul>

		
		 <p class="options"><a class="affiliations-toggle" href="#"><i class="arrow"></i>Author Affiliations</a></p>            <section> 
						<div class="collapsible-content">
							
				<div id="ins_container" style="display: block;">
										    						    <p >
						        <sup id="ins1">1</sup>                                University of Queensland Centre for Clinical Research, Building 71/918 Royal Brisbane & Women’s Hospital Campus, Herston, Brisbane, 4029, QLD, Australia
                            </p>
																    						    <p >
						        <sup id="ins2">2</sup>                                Department of Infectious Diseases, The Alfred Hospital, Melbourne, VIC, Australia
                            </p>
																    						    <p >
						        <sup id="ins3">3</sup>                                Westmead Millenium Institute for Medical Research, Westmead Hospital, Sydney, NSW, Australia
                            </p>
																    						    <p >
						        <sup id="ins4">4</sup>                                Department of Microbiology and Infectious Diseases, Royal Perth Hospital, Perth, WA, Australia
                            </p>
																    						    <p >
						        <sup id="ins5">5</sup>                                School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, WA, Australia
                            </p>
																    						    <p >
						        <sup id="ins6">6</sup>                                Department of Infectious Diseases, School of Medicine, University of Wollongong and The Wollongong Hospital, Wollongong, NSW, Australia
                            </p>
																    						    <p >
						        <sup id="ins7">7</sup>                                Department of Infectious Diseases, Austin Health, Melbourne, VIC, Australia
                            </p>
																    						    <p >
						        <sup id="ins8">8</sup>                                Monash Infectious Disease, Monash Health, Clayton, VIC, Australia
                            </p>
																    						    <p >
						        <sup id="ins9">9</sup>                                Victorian Infectious Diseases Unit, Royal Melbourne Hospital, Melbourne, VIC, Australia
                            </p>
																    						    <p >
						        <sup id="ins10">10</sup>                                Burns Trauma and Critical Care Research Centre, The University of Queensland, Brisbane, QLD, Australia
                            </p>
																    						    <p >
						        <sup id="ins11">11</sup>                                Department of Infectious Disease, Barwon Health, Deakin University, Geelong, VIC, Australia
                            </p>
																    						    <p >
						        <sup id="ins12">12</sup>                                Clinical Trials & Biostatistics Unit, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
                            </p>
																    						    <p >
						        <sup id="ins13">13</sup>                                Queensland Clinical Trials and Biostatistics Centre, University of Queensland, Brisbane, QLD, Australia
                            </p>
																
				</div>
										<p id="authoremails">            For all author emails, please <a href="/logon">log on</a>.
    </p>
						</div>
			</section>
				</div>
</div>
		</div>
	  </div>

            <section class="cit">
                        <div class="collapsible-content">
        <p><em>Trials</em> 2015, <strong>16</strong>:24&nbsp;
			<span class="pseudotab">doi:10.1186/s13063-014-0541-9</span></p>
	    				    
    
        
                
		<p>The electronic version of this article is the complete one and can be found online at: <a href="http://www.trialsjournal.com/content/16/1/24">http://www.trialsjournal.com/content/16/1/24</a></p>
		<br/>
                    <table cellspacing="0" cellpadding="0">
        <tbody>
        <tr><td>Received:</td><td>21 September 2014</td></tr>                <tr><td>Accepted:</td><td>22 December 2014</td></tr>        <tr><td>Published:</td><td>27 January 2015</td></tr>        </tbody>
        </table>
    		<!--<br/>-->
		<div  style="line-height:140%">
        <p>
            &copy; 2015 Harris et al.; licensee BioMed Central. <br />
        </p>
					<p>
				This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<a href='http://creativecommons.org/licenses/by/4.0'>http://creativecommons.org/licenses/by/4.0</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
			</p>
		    	</div>
	</section>

</div>
<div id="article-body">
    <section><a name="abs"></a><h3>Abstract</h3>
   <div class="collapsible-content">
      <h4>Background</h4>
      <p style="line-height:160%">Gram-negative bacteria such as <em>Escherichia coli</em> or <em>Klebsiella</em> spp. frequently cause bloodstream infections. There has been a worldwide increase
         in resistance in these species to antibiotics such as third generation cephalosporins,
         largely driven by the acquisition of extended-spectrum beta-lactamase or plasmid-mediated
         AmpC enzymes. Carbapenems have been considered the most effective therapy for serious
         infections caused by such resistant bacteria; however, increased use creates selection
         pressure for carbapenem resistance, an emerging threat arising predominantly from
         the dissemination of genes encoding carbapenemases. Recent retrospective data suggest
         that beta-lactam/beta-lactamase inhibitor combinations, such as piperacillin-tazobactam,
         may be non-inferior to carbapenems for the treatment of bloodstream infection caused
         by extended-spectrum beta-lactamase-producers, if susceptible <em>in vitro</em>. This study aims to test this hypothesis in an effort to define carbapenem-sparing
         alternatives for these infections.
      </p>
      <h4>Methods/Design</h4>
      <p style="line-height:160%">The study will use a multicentre randomised controlled open-label non-inferiority
         trial design comparing two treatments, meropenem (standard arm) and piperacillin-tazobactam
         (carbapenem-sparing arm) in adult patients with bacteraemia caused by <em>E. coli</em> or <em>Klebsiella</em> spp. demonstrating non-susceptibility to third generation cephalosporins. Recruitment
         is planned to occur in sites across three countries (Australia, New Zealand and Singapore).
         A total sample size of 454 patients will be required to achieve 80% power to determine
         non-inferiority with a margin of 5%. Once randomised, definitive treatment will be
         for a minimum of 4 days, but up to 14 days with total duration determined by treating
         clinicians. Data describing demographic information, antibiotic use, co-morbid conditions,
         illness severity, source of infection and other risk factors will be collected. Vital
         signs, white cell count, use of vasopressors and days to bacteraemia clearance will
         be recorded up to day 7. The primary outcome measure will be mortality at 30 days,
         with secondary outcomes including days to clinical and microbiological resolution,
         microbiological failure or relapse, isolation of a multi-resistant organism or <em>Clostridium difficile</em> infection.
      </p>
      <h4>Trial registration</h4>
      <p style="line-height:160%">The MERINO trial is registered under the Australian New Zealand Clinical Trials Register
         (ANZCTR), reference number: <a href="ACTRN12613000532707">ACTRN12613000532707</a> <a href="http://www.webcitation.org/query.php?url=ACTRN12613000532707&amp;refdoi=10.1186/s13063-014-0541-9" alt="" title="Archive copy of webpage" class="xpushbutton">webcite</a> (registered 13 May 2013) and the US National Institute of Health ClinicalTrials.gov
         register, reference number: <a href="NCT02176122">NCT02176122</a> <a href="http://www.webcitation.org/query.php?url=NCT02176122&amp;refdoi=10.1186/s13063-014-0541-9" alt="" title="Archive copy of webpage" class="xpushbutton">webcite</a> (registered 24 June 2014).
      </p>
   </div>
</section><span id="keywords">
   <h5 class="inline">Keywords: </h5>Extended-spectrum beta-lactamase; ESBL; Plasmid-AmpC; Therapy; Resistance; Beta-lactam/beta-lactamase inhibitor; Carbapenem; Clinical trial</span><section><a name="sec1"></a><h3>Background</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">Bloodstream infections caused by Gram-negative bacteria such as <em>Escherichia coli</em> or <em>Klebsiella</em> spp. are commonly encountered in clinical practice and may be associated with significant
         mortality <a name="d72686e335"></a>[<a onclick="LoadInParent('#B1'); return false;" href="#B1">1</a>]. These bacteria may also acquire genes encoding beta-lactamase enzymes that hydrolyse
         essential beta-lactam antibiotics, rendering such treatment ineffective. Isolates
         expressing extended-spectrum beta-lactamase (ESBL) or plasmid-mediated AmpC enzymes
         are increasingly encountered across the world, in both community- and hospital-onset
         infections <a name="d72686e339"></a>[<a onclick="LoadInParent('#B2'); return false;" href="#B2">2</a>]. ESBL- or AmpC-producers are typically resistant to third generation cephalosporins
         such as ceftriaxone, but susceptible to carbapenems <a name="d72686e343"></a>[<a onclick="LoadInParent('#B3'); return false;" href="#B3">3</a>]. These bacteria are usually multi-resistant, as beta-lactamase genes are frequently
         co-located with other resistance mechanisms, leaving few treatment options. Bacteraemia
         caused by resistant Gram-negative bacteria may carry mortality in excess of those
         caused by susceptible strains <a name="d72686e348"></a>[<a onclick="LoadInParent('#B4'); return false;" href="#B4">4</a>]. Thus, defining optimal treatment regimens in these serious infections is of clinical
         importance. However, when selecting antimicrobial therapy, clinicians must consider
         both efficacy of the chosen agent and downstream risk such as selective pressure for
         further antimicrobial resistance.
      </p>
      <p style="line-height:160%">In observational studies that have been performed to evaluate antibiotic choices for
         ESBL-producing Enterobacteriaceae, no agent has been shown to significantly surpass
         carbapenems <a name="d72686e354"></a>[<a onclick="LoadInParent('#B5'); return false;" href="#B5">5</a>]-<a name="d72686e358"></a>[<a onclick="LoadInParent('#B8'); return false;" href="#B8">8</a>]. However, widespread use of carbapenems may cause selection pressure for carbapenem
         resistance <a name="d72686e362"></a>[<a onclick="LoadInParent('#B9'); return false;" href="#B9">9</a>],<a name="d72686e366"></a>[<a onclick="LoadInParent('#B10'); return false;" href="#B10">10</a>]. Carbapenem-resistant Gram-negative bacteria present a great therapeutic challenge,
         with susceptibility often limited to ‘last-line’ antibiotics such as colistin or tigecycline.
         Some new beta-lactam antibiotics and beta-lactamase inhibitors, which are active against
         ESBL-, AmpC- and some carbapenemase-producing organisms, are in advanced clinical
         development <a name="d72686e370"></a>[<a onclick="LoadInParent('#B11'); return false;" href="#B11">11</a>],<a name="d72686e375"></a>[<a onclick="LoadInParent('#B12'); return false;" href="#B12">12</a>]. However, these antibiotics are likely to be expensive, are not yet on the market
         and may best be held in reserve for infections without therapeutic alternatives.
      </p>
      <p style="line-height:160%">The susceptibility of AmpC- and ESBL-producers to piperacillin-tazobactam is less
         predictable than carbapenems. By definition, ESBLs are inhibited by beta-lactamase
         inhibitors such as clavulanate or tazobactam <a name="d72686e381"></a>[<a onclick="LoadInParent('#B3'); return false;" href="#B3">3</a>]. However, <em>E. coli</em> or <em>Klebsiella</em> spp. may also produce multiple beta-lactamase types, some of which are resistant
         to inhibition by tazobactam and may not be evident by susceptibility testing alone.
         There have also been concerns that inoculum effects may overwhelm the activity of
         beta-lactamase inhibition in infections with a large bacterial burden <a name="d72686e391"></a>[<a onclick="LoadInParent('#B13'); return false;" href="#B13">13</a>]. Additionally, in some cases outer membrane protein loss may contribute to resistance
         to tazobactam <a name="d72686e395"></a>[<a onclick="LoadInParent('#B14'); return false;" href="#B14">14</a>]. By definition, AmpC enzymes are also not well inhibited by tazobactam <a name="d72686e400"></a>[<a onclick="LoadInParent('#B15'); return false;" href="#B15">15</a>], and plasmid-mediated AmpC expression has been increasingly recognised as a cause
         of resistance to expanded spectrum cephalosporins in Enterobacteriaceae <a name="d72686e404"></a>[<a onclick="LoadInParent('#B15'); return false;" href="#B15">15</a>]. However, despite these concerns, approximately 50% or more of ceftriaxone non-susceptible
         <em>E. coli</em> or <em>Klebsiella</em> spp. remain susceptible to piperacillin-tazobactam <a name="d72686e414"></a>[<a onclick="LoadInParent('#B16'); return false;" href="#B16">16</a>]. Yet, until recently, lack of published clinical experience with the use of beta-lactam/beta-lactamase
         inhibitor (BLBLI) agents for the treatment of ESBL-producers has limited their use.
         As a result, carbapenems have been perceived as a superior option. In recent years
         we have witnessed an alarming increase in the prevalence and global dissemination
         of carbapenem-resistant Gram-negative bacteria, largely driven by the spread of genes
         encoding carbapenemase enzymes, transmitted on highly mobile plasmids <a name="d72686e418"></a>[<a onclick="LoadInParent('#B17'); return false;" href="#B17">17</a>]. Thus, defining carbapenem-sparing treatment options for ESBL-producers has become
         imperative to reduce the selection pressure for carbapenem resistance <a name="d72686e423"></a>[<a onclick="LoadInParent('#B10'); return false;" href="#B10">10</a>].
      </p>
      <p style="line-height:160%">No randomised controlled trials (RCTs) have yet been performed comparing different
         treatment options for third generation cephalosporin-resistant Enterobacteriaceae.
         The largest observational study with an analysis by treatment outcome was published
         in 2012 by Rodriguez-Bano <em>et al</em>. <a name="d72686e432"></a>[<a onclick="LoadInParent('#B18'); return false;" href="#B18">18</a>]. They performed a <em>post hoc</em> analysis of six prospective cohorts of patients with bacteraemia due to ESBL-producing
         <em>E. coli</em>. Two non-mutually exclusive cohorts (empirical therapy and definitive therapy) were
         constructed and analysed separately. In both cohorts, carbapenems were not superior
         to BLBLI combinations, such as piperacillin-tazobactam. Specifically, in the definitive
         therapy cohort, mortality rates at 30 days were not significantly different - 9.3%
         for those who received a BLBLI and 16.7% for those who received a carbapenem (<em>P</em> &gt; 0.20) <a name="d72686e446"></a>[<a onclick="LoadInParent('#B18'); return false;" href="#B18">18</a>]. A subsequent meta-analysis of all published studies examining treatment options
         for bacteraemia caused by ESBL-producers also concluded that BLBLI agents were non-inferior
         to carbapenems for both definitive (relative risk (RR) 0.52, 95% confidence interval
         (CI) 0.23 to 1.13) or empirical therapy (RR 0.91, 95% CI 0.66 to 1.25) with regard
         to all-cause mortality <a name="d72686e450"></a>[<a onclick="LoadInParent('#B6'); return false;" href="#B6">6</a>]. In contrast, mortality was lower with carbapenems when compared to non-BLBLI antibiotics
         (for example, quinolones) for both definitive (RR 0.65, 95% CI 0.47 to 0.91) and empirical
         treatment (RR 0.50, 95% CI 0.33 to 0.77).
      </p>
      <p style="line-height:160%">Both meropenem and piperacillin-tazobactam are antibiotics that have been widely used
         in clinical practice for many years. They have proven efficacy in a wide range of
         infectious syndromes, including severe sepsis, febrile neutropenia, ventilator-associated
         pneumonia and intra-abdominal sepsis. Both agents are licensed for the treatment of
         serious infections and are available for routine clinical use in generic formulations.
         A non-inferiority study design was selected because it is not ethically possible to
         conduct a placebo-controlled trial and piperacillin-tazobactam is not expected to
         be superior to meropenem with regard to the primary end-point. Instead, potential
         benefits relate to minimisation of ‘collateral damage’ in the form of selection for
         carbapenem-resistant Enterobacteriaceae.
      </p>
   </div>
</section>
<section><a name="sec2"></a><h3>Methods/Design</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">The trial protocol was developed by the Gram-negative Working Group of the Australasian
         Society for Infectious Disease Clinical Research Network (ASID-CRN), in accordance
         with the CONSORT statement extension for ‘Non-inferiority and Equivalence Trials’
         <a name="d72686e462"></a>[<a onclick="LoadInParent('#B19'); return false;" href="#B19">19</a>].
      </p>
      <h4>Hypothesis</h4>
      <p style="line-height:160%">Our hypothesis is that piperacillin-tazobactam is non-inferior to meropenem for the
         definitive treatment of bloodstream infections due to third generation cephalosporin
         non-susceptible <em>E. coli</em> or <em>Klebsiella</em> spp.
      </p>
      <h4>Study design</h4>
      <p style="line-height:160%">The study design will be a multicentre randomised controlled non-inferiority open-label
         phase III trial. Both study drugs (meropenem and piperacillin-tazobactam) will be
         administered intravenously with standard dosing regimens. The study population will
         be all adult patients (18 years of age or older, or 21 years or older at Singapore
         sites) admitted to participating hospitals. Inclusion in the study will be determined
         by the presence of a bloodstream infection with <em>E. coli</em> or <em>Klebsiella</em> spp., as defined by at least one positive blood culture from a peripheral blood draw,
         where the isolate is confirmed to be third generation cephalosporin non-susceptible,
         but susceptible to piperacillin-tazobactam and meropenem by European Committee for
         Antimicrobial Susceptibility Testing (EUCAST) standards <a name="d72686e490"></a>[<a onclick="LoadInParent('#B20'); return false;" href="#B20">20</a>].
      </p>
      <h4>Setting</h4>
      <p style="line-height:160%">The trial will be conducted in several centres across Australia, New Zealand and Singapore
         (see Table&nbsp;<a name="d72686e499"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/24/table/T1','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/24/table/T1">1</a>).
         
      </p><div class="figs">
      <div class="table"><p><a onclick="popup('http://www.trialsjournal.com/content/16/1/24/table/T1','T1',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/24/table/T1"><strong>Table 1.</strong></a> <strong>Proposed participating sites</strong></div></div>
      <h4>Intervention</h4>
      <p style="line-height:160%">Meropenem 1 gram will be administered every 8 hours intravenously or piperacillin-tazobactam
         4.5 grams administered every 6 hours intravenously. Each dose will be given over 30
         minutes. The study drug is to be administered for a minimum of 4 days and can be given
         for as long as 14 days. The total duration of therapy will be determined by the treating
         clinician. Dose adjustment for renal impairment will be made according to the criteria
         in Table&nbsp;<a name="d72686e633"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/24/table/T2','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/24/table/T2">2</a>. Blinding will not be performed as the two antibiotics have different dosing regimens.
         Follow-up will be for 30 days post enrolment. Other antimicrobials active against
         Gram-negative bacilli are excluded in the first 4 days after enrolment, except that
         trimethoprim/sulfamethoxazole may be continued as <em>Pneumocystis</em> prophylaxis.
         
      </p><div class="figs">
      <div class="table"><p><a onclick="popup('http://www.trialsjournal.com/content/16/1/24/table/T2','T2',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/24/table/T2"><strong>Table 2.</strong></a> <strong>Dose adjustment for study antibiotics</strong></div></div>
      <h4>Primary objectives</h4>
      <p style="line-height:160%"> To compare the 30-day mortality post bloodstream infection in patients treated with
         piperacillin-tazobactam or meropenem
      </p>
      <h4>Secondary objectives</h4>
      <p style="line-height:160%"> To compare the time to clinical and microbiologic resolution of infection for each
         regimen, defined as: number of days from randomisation to resolution of fever (temperature &gt; 38.0°C)
         and leucocytosis (white blood cell count &gt; 12 × 10<sup>9</sup>/L) PLUS sterilisation of blood cultures
      </p>
      <p style="line-height:160%"> To compare the clinical and microbiologic success of each regimen at day 4 of the
         intervention, defined as survival PLUS resolution of fever and leucocytosis PLUS sterilisation
         of blood cultures. All of these criteria will be assessed on day 4, counted from the
         day of randomisation (day 1) in order to determine a rapid response from the trial
         drug
      </p>
      <p style="line-height:160%"> To compare microbiologic resolution of infection, defined as sterility of blood cultures
         collected on or before day 4
      </p>
      <p style="line-height:160%"> To compare the risk of relapse with each regimen, defined as growth of the same organism
         as in the original blood culture after the end of the period of study drug administration
         but before day 30
      </p>
      <p style="line-height:160%"> To compare the risk of superinfection with a carbapenem or piperacillin-tazobactam-
         resistant organism or <em>Clostridium difficile</em>, defined as growth of a meropenem or piperacillin-tazobactam-resistant organism from
         any clinical specimen collected from day 4 of study drug administration to day 30
         or a positive <em>C. difficile</em> stool test (with the method of testing used according to local laboratory protocol).
         This endpoint is important since one of the purposes of establishing an alternative
         to carbapenem therapy is to reduce infections with resistant organisms or <em>C. difficile</em>.
      </p>
      <h4>Randomisation</h4>
      <p style="line-height:160%">Patients will be randomly assigned to either meropenem or piperacillin-tazobactam
         in a 1:1 ratio according to a randomisation list prepared in advance for each recruiting
         site and stratification. Random sequence will be generated using random permuted blocks
         of unequal length. The randomisation process will be managed by the Queensland Clinical
         Trials &amp; Biostatistics Centre (QCTBC) of The University of Queensland, and generated
         using an online data management system (REDCap). Patients will be stratified into
         4 groups according to infecting species (<em>E. coli</em> or <em>Klebsiella</em> spp.) and disease severity (according to a Pitt bacteraemia score <a name="d72686e778"></a>[<a onclick="LoadInParent('#B21'); return false;" href="#B21">21</a>] ≤ 4 or &gt; 4; and presumed site of infection from the urinary tract or elsewhere) (see
         Figure&nbsp;<a name="d72686e781"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/24/figure/F1','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/24/figure/F1">1</a>).
         
      </p><div class="figs">
      <div class="fig"><p><a onclick="popup('http://www.trialsjournal.com/content/16/1/24/figure/F1','F1',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/24/figure/F1"><img align="top" src="/content/figures/s13063-014-0541-9-1.gif" alt="thumbnail" class="thumbnail"><strong>Figure 1.</strong></a> <strong>Patient stratification at enrolment.</strong></div></div>
      <h4>Safety monitoring plan</h4>
      <p style="line-height:160%">A Data Monitoring and Safety Board (DMSB) will be established, comprising two independent
         infectious disease physicians with statistical support provided to them by the QCTBC.
         An interim analysis - including both efficacy and safety endpoints - will be performed
         after the first 50 subjects have completed the 30-day study period. The trial statistician
         will provide details of safety outcomes and any significant differences in primary
         outcomes according to treatment arm to the DMSB. The stopping rule would be a statistically
         significant difference in primary outcomes between the two therapies.
      </p>
      <h4>Data entry and storage</h4>
      <p style="line-height:160%">A clinical database using the REDCap trial data management system has been developed
         with a web hosting facility. Paper case report forms (CRFs) (Additional file <a name="d72686e808"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/24/suppl/S1','',630,470); return false;" href="http://www.trialsjournal.com/content/16/1/24/suppl/S1">1</a>) will be completed and uploaded to the online system to collect all clinical and
         additional laboratory-related information (see Table&nbsp;<a name="d72686e811"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/24/table/T3','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/24/table/T3">3</a>). To ensure accurate transcription of the CRF, double-data entry will be performed
         by a second independent researcher. Any discrepancies, missing data or errors will
         be clarified by discussion with the site principal investigator. To ensure validity,
         a proportion of CRFs will be checked by the local site investigators against clinical
         and laboratory records.
         
      </p><div class="figs">
      <div class="table"><p><a onclick="popup('http://www.trialsjournal.com/content/16/1/24/table/T3','T3',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/24/table/T3"><strong>Table 3.</strong></a> <strong>Data collection</strong></div></div>
      <h4>Determination of sample size</h4>
      <p style="line-height:160%">As no randomised clinical trial has yet been conducted in this particular field, the
         sample size estimation has been derived from the retrospective study of bloodstream
         infection caused by ESBL-producing <em>E. coli</em> performed by Rodriguez-Bano <em>et al</em>. <a name="d72686e958"></a>[<a onclick="LoadInParent('#B7'); return false;" href="#B7">7</a>]. The overall 30-day mortality in their study was 16.7% in those patients who received
         a carbapenem (our control group). We have conducted a series of simulations with possible
         variations in the observed rates between the two treatment groups. Considering a mortality
         rate of 17% in the control group (rounded from the 16.7% actually observed), and a
         non-inferiority margin of 5% difference in the 2 groups, we would need 280 patients
         in total to achieve 80% power with a 1-sided alpha level of 0.025. This allows for
         10% dropout. It is likely that mortality rates in observational cohorts may be greater
         than those in a trial with exclusion criteria. Therefore, if the observed mortality
         rate in the control group was 14% (3% lower than that seen in the observational cohort),
         then under the same assumptions, we would need 454 patients in total to achieve 80%
         power <a name="d72686e962"></a>[<a onclick="LoadInParent('#B22'); return false;" href="#B22">22</a>].
      </p>
      <p style="line-height:160%">Actual mortality is expected to be similar in our study population. We have performed
         a retrospective analysis of 92 bacteraemia episodes caused by ceftriaxone-resistant
         <em>E. coli</em> or <em>Klebsiella</em> in Singapore (one of the trial sites) over a 12-month period until May 2013, examining
         patients that would fulfil the MERINO trial inclusion criteria. Average mortality
         at 30 days was 17.4% in patients given a carbapenem for definitive therapy. However,
         overall mortality for all treatment groups was lower at 8.7%, including those receiving
         BLBLIs (8.3%) <a name="d72686e974"></a>[<a onclick="LoadInParent('#B23'); return false;" href="#B23">23</a>].
      </p>
      <h4>Statistical and analytical plans</h4>
      <p style="line-height:160%">The intention-to-treat (ITT) analysis approach, supported by the per-protocol approach,
         will be adopted to make inference on the possible non-inferiority of the treatment
         arm, compared to the control arm, in terms of 30-day mortality. The proportions of
         deaths (with 95% CIs) in the 2 study arms will be calculated. Logistic regression
         with ‘treatment group’ as the only covariate will be employed to draw inference on
         the possible non-inferiority of the intervention treatment compared to the control
         treatment. The odds ratio (with 95% CIs) will be calculated with the meropenem arm
         as the reference group. Appropriate parametric or non-parametric statistical techniques
         will be employed to analyse the data for secondary aims of the study. The Mann–Whitney
         <em>U</em>-test will be used to compare median number of days to clinical and microbiological
         resolution. Logistic regression will be used to compare odds ratios of achieving clinical
         and microbiological success and microbiological resolution at day 4, as well as the
         odds ratio for microbiological relapse and superinfection with a resistant organism
         between each treatment arm. All secondary analyses will be based on an ITT population.
      </p>
      <p style="line-height:160%">An analysis of primary and secondary endpoints as described above will be undertaken
         in a subgroup of ‘high risk’ patients defined by a likely source of infection other
         than the urinary tract or a Pitt bacteraemia score of &gt;4.
      </p>
      <p style="line-height:160%">Basic statistics in the study report will include information on missing values for
         all relevant study variables. A summary of baseline patient characteristics with totals
         and proportions (%) for categorical variables, and minimum, maximum, inter-quartile
         ranges and standard deviations for continuous variables will be presented. For continuous
         study variables, box plots and Kernel density plots will also be provided.
      </p>
      <h4>Protocol violations</h4>
      <p style="line-height:160%">All protocol violations occurring after randomisation will be listed in the Clinical
         Study Report, tabulated by subject and recruitment site. The final assignment of participants
         to the per-protocol analysis population will be made at a blinded protocol violation
         review meeting prior to database lock.
      </p>
      <h4>Consent</h4>
      <p style="line-height:160%">Potential study participants will be identified on the basis of positive blood cultures
         by liaison between the investigators and the clinical microbiologists. All patients
         who fulfill the microbiological inclusion criteria will be screened for eligibility
         using a standardised screening form (see Additional file <a name="d72686e1002"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/24/suppl/S2','',630,470); return false;" href="http://www.trialsjournal.com/content/16/1/24/suppl/S2">2</a>). The investigators will only approach the patient with the agreement of the treating
         team. As soon as practically possible after this discussion, the study team representative
         will approach the patient at the bedside to obtain consent. Typically this will be
         around 48 to 72 hours after the onset of clinical sepsis and the initial collection
         of blood cultures. For patients with cognitive impairment secondary to their illness
         (for example, intubation and ventilation, delirium), consent will be obtained from
         a legally appropriate representative (for example, spouse), where local regulatory
         requirements allow recruitment of cognitively-impaired persons to clinical trials.
      </p>
      <h4>Study preparation and logistics</h4>
      <p style="line-height:160%">The trial coordination centre comprises the project management team (THB, PH and DLP)
         at the University of Queensland Centre for Clinical Research in Brisbane. Site initiation
         and training will be conducted by PH, DLP and THB via web conferencing and/or site
         visits. Study sites will be contacted regularly via teleconference to discuss any
         issues and ensure consistent study practices across sites.
      </p>
      <h4>Laboratory studies</h4>
      <p style="line-height:160%">All blood culture isolates will be made available to the central trial laboratory
         at the University of Queensland Centre for Clinical Research. Susceptibility testing,
         including minimum inhibitory concentrations for key antimicrobials, will be repeated
         in the central laboratory and interpreted according to EUCAST standards. Additional
         susceptibility testing for agents not tested at the recruiting site laboratories will
         also be performed. Phenotypic confirmation of ESBL or AmpC production will be performed
         using combination disc testing <a name="d72686e1018"></a>[<a onclick="LoadInParent('#B24'); return false;" href="#B24">24</a>]. Beta-lactamase genes will be identified and characterized. Isolates will also be
         screened for carbapenemase genes and other key antimicrobial resistance determinants.
         Strain typing will be determined using methods such as semi-automated repetitive sequence-based
         PCR (rep-PCR) (DiversiLab; BioMérieux, Marcy l’Étoile, France) and multi-locus sequence
         typing (MLST). Isolates will also be available for whole genome sequencing.
      </p>
      <h4>Ethics</h4>
      <p style="line-height:160%">The protocol has been given ethical approval by the Royal Brisbane and Women’s Hospital
         (ref: HREC/12/QRBW/440), the National Healthcare Group (NHG) Domain Specific Review
         Board (DSRB) in Singapore (NHG DSRB ref: 2013/00453) and the New Zealand Health and
         Disability Ethics Committee (Ref: 14/NTB/52).
      </p>
   </div>
</section>
<section><a name="sec3"></a><h3>Discussion</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">The quality and extent of evidence to help define optimal treatment for many significant
         bacterial infections is surprisingly limited. This is especially true for the treatment
         of resistant Gram-negative bacteraemia, despite being a major issue in daily practice
         for clinicians across many specialties. In addition to laboratory data and expert
         opinion, current practice is almost entirely based on retrospective observational
         studies, usually conducted in single centres with relatively small numbers of patients.
         Such studies, though informative, are always prone to bias, thus weakening the strength
         of conclusions drawn for these analyses. To date, there have been no RCTs reported
         specifically comparing different treatment options for ceftriaxone-resistant Enterobacteriaceae.
      </p>
      <p style="line-height:160%">There is local support for the conduct of this study. This is highlighted by a recent
         online survey in which 122 infectious diseases physicians in Australia and New Zealand
         were asked to rank the research studies of greatest immediate clinical relevance -
         the proposed trial comparing meropenem and piperacillin-tazobactam was the highest
         ranked RCT in the field of antibiotic resistance in Gram-negative bacilli <a name="d72686e1036"></a>[<a onclick="LoadInParent('#B25'); return false;" href="#B25">25</a>].
      </p>
      <p style="line-height:160%">Antibiotic resistance is of tremendous public health importance and has been recently
         described as potentially the greatest current threat to human health <a name="d72686e1042"></a>[<a onclick="LoadInParent('#B26'); return false;" href="#B26">26</a>]. The MERINO trial has potential significance for two reasons. Firstly, it addresses
         treatment of a common but serious antibiotic resistance issue that is associated with
         10 to 20% mortality <a name="d72686e1046"></a>[<a onclick="LoadInParent('#B5'); return false;" href="#B5">5</a>],<a name="d72686e1050"></a>[<a onclick="LoadInParent('#B18'); return false;" href="#B18">18</a>]. Secondly, proving that a carbapenem-sparing antibiotic regimen is non-inferior to
         a carbapenem will help encourage use of alternatives to carbapenems. Carbapenem resistance
         is the ‘end-game’ with respect to antibiotic resistance as it eliminates one of our
         most important antibiotic options and leaves few effective alternative treatments.
         Evidenced-based strategies to support the clinical management of resistant infections
         that consider both efficacy and the potential for ‘collateral damage’ of treatment
         options are therefore urgently needed.
      </p>
   </div>
</section>
<section><a name="sec4"></a><h3>Trial status</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">A pilot study based on this protocol has commenced recruitment in both Singapore and
         Australia in February 2014. The remaining study sites are scheduled to begin enrolment
         later during 2014 once local regulatory requirements have been completed. It is planned
         for the pilot phase to be extended to a definitive trial in early 2015. It is aimed
         that recruitment for the definitive study will be completed by late 2016. Data from
         the pilot phase will be included in the definitive study analysis.
      </p>
   </div>
</section>
<section><a name="sec5"></a><h3>Abbreviations</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">APACHE: Acute Physiology and Chronic Health Evaluation</p>
      <p style="line-height:160%">ASID: Australasian Society for Infectious Disease</p>
      <p style="line-height:160%">BLBLI: beta-lactam/beta-lactamase inhibitor</p>
      <p style="line-height:160%">CRF: Clinical record form</p>
      <p style="line-height:160%">CRN: Clinical Research Network</p>
      <p style="line-height:160%">DMSB: Data Monitoring and Safety Board</p>
      <p style="line-height:160%">DSRB: Domain Specific Review Board</p>
      <p style="line-height:160%">ESBL: extended-spectrum beta-lactamase</p>
      <p style="line-height:160%">EUCAST: European Committee for Antimicrobial Susceptibility Testing</p>
      <p style="line-height:160%">QCTBC: Queensland Clinical Trials and Biostatistics Unit</p>
      <p style="line-height:160%">ITT: intention-to-treat</p>
      <p style="line-height:160%">MLST: multi-locus sequence typing</p>
      <p style="line-height:160%">NHG: National Healthcare Group</p>
      <p style="line-height:160%">PCR: polymerase chain reaction</p>
      <p style="line-height:160%">QCTBC: Queensland Clinical Trials and Biostatistics Unit</p>
      <p style="line-height:160%">RCTs: randomised controlled trials</p>
      <p style="line-height:160%">RR: relative risk</p>
   </div>
</section>
<section><a name="sec6"></a><h3>Competing interests</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">SKP has acted as a consultant and speaker for Novartis and Amylin Pharmaceuticals,
         LLC. He has received grants in support of investigator and investigator initiated
         clinical studies from Merck, Novo Nordisk and Pfizer, Bristol Myer Squib, Amylin Pharmaceuticals
         and Hospira. SKP also received an infrastructure research grant from Therapeutic Innovations
         Australia. DLP has participated in advisory boards and received honoraria from AstraZeneca,
         Merck, Pfizer, Bayer, Cubist and Leo Pharmaceuticals. All other authors have no competing
         interests to declare.
      </p>
   </div>
</section>
<section><a name="sec7"></a><h3>Authors’ contributions</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">PH wrote the initial and final drafts of the manuscript. The concept for the study
         was proposed by AYP and DLP. The original protocol was developed by the Gram-negative
         Working Group of the ASID-CRN (AYP, JI, PRI, SM, AS, BAR, ESM, EA, THB and DLP) with
         additional input from JL and JAR. Statistical support was provided by SKP and PB.
         All authors have reviewed the final manuscript and approve its contents.
      </p>
   </div>
</section>
<section><a name="sec8"></a><h3>Authors’ information</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">PH is an infectious disease physician and microbiologist and is currently undertaking
         a PhD with the Paterson group at UQCCR. AYP is an infectious disease physician and
         NHMRC Career Development Fellow. ESM is an infectious diseases physician and is the
         head of epidemiology at the Victorian Infectious Diseases Service. SM is a clinical
         academic infectious diseases and general medicine physician. AJS is an infectious
         diseases physician. PRI is an infectious diseases physician and microbiologist. BAR
         is an infectious disease physician. JL is a critical care specialist. JAR is a clinical
         pharmacist and NHMRC Research Fellow. JI is a physician and microbiologist and runs
         the NHMRC Centre for Research Excellence in Critical Infection in Sydney. EA is an
         infectious disease physician. SKP is a clinical trialist and biostatistician. PB is
         a statistician. THB is a registered nurse and is currently the Clinical Research Manager
         for the Paterson group at UQCCR. DLP is an infectious disease physician and microbiologist
         and chairs the ASID-CRN steering committee.
      </p>
   </div>
</section>
<section><a name="sec9"></a><h3>Additional files</h3>
   <div class="collapsible-content"><div class="figs">
      <div class="addfile"><p><a onclick="popup('http://www.trialsjournal.com/content/16/1/24/suppl/S1','S1',630,470); return false;" href="http://www.trialsjournal.com/content/16/1/24/suppl/S1"></a><strong>Additional file 1:.</strong> <strong>MERINO Trial Clinical Record Form.</strong></p><p>
         	Format: DOCX 
         	Size: 1.5MB <a href="/content/supplementary/s13063-014-0541-9-s1.docx">Download file</a><span class="open-data-icon"><a href="/about/access/#opendata"><img title="Open Data" alt="Open Data" src="/bmcimages/article/opendata.gif"></a></span></div>
      <div class="addfile"><p><a onclick="popup('http://www.trialsjournal.com/content/16/1/24/suppl/S2','S2',630,470); return false;" href="http://www.trialsjournal.com/content/16/1/24/suppl/S2"></a><strong>Additional file 2:.</strong> <strong>MERINO Trials Initial Screening Form.</strong></p><p>
         	Format: DOCX 
         	Size: 28KB <a href="/content/supplementary/s13063-014-0541-9-s2.docx">Download file</a><span class="open-data-icon"><a href="/about/access/#opendata"><img title="Open Data" alt="Open Data" src="/bmcimages/article/opendata.gif"></a></span></div></div>
   </div>
</section>
<section><a name="ack"></a><h3>Acknowledgments</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">Funding for the trial has been received from the Australasian Society for Antimicrobials
         (ASA) and the International Society for Chemotherapy (ISC). We would like to acknowledge
         Anna Sartor (UQCCR) and Simon Forsyth (QCTBC) for assistance in setting up the REDCap
         database and all local site investigators for their involvement.
      </p>
      <p style="line-height:160%">On behalf of the Australasian Society for Infectious Diseases Clinical Research Network
         (ASID-CRN).
      </p>
   </div>
</section>
<section><a name="refs"></a><h3>References</h3>
   <div id="article-references" class="collapsible-content">
      <ol id="references">
         <li id="B1">
            <p><a name="B1"></a> Cohen J,  Cristofaro P,  Carlet J,  Opal S: <strong> New method of classifying infections in critically ill patients. </strong><p><em>Crit Care Med</em> 2004,  <strong>32</strong>(7)<strong>:</strong>1510-26.  <a target="_blank" href="/pubmed/15241096">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=15241096">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0541-9&amp;bibl=B1" onclick="popup('/sfx_links?ui=s13063-014-0541-9&amp;bibl=B1','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B2">
            <p><a name="B2"></a> Pitout JD,  Laupland KB: <strong> Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health
                  concern. </strong><p><em>Lancet Infect Dis</em> 2008,  <strong>8</strong>(3)<strong>:</strong>159-66.  <a target="_blank" href="/pubmed/18291338">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=18291338">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0541-9&amp;bibl=B2" onclick="popup('/sfx_links?ui=s13063-014-0541-9&amp;bibl=B2','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B3">
            <p><a name="B3"></a> Paterson DL,  Bonomo RA: <strong> Extended-spectrum beta-lactamases: a clinical update. </strong><p><em>Clin Microbiol Rev</em> 2005,  <strong>18</strong>(4)<strong>:</strong>657-86.  <a target="_blank" href="/pubmed/16223952">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=16223952">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0541-9&amp;bibl=B3" onclick="popup('/sfx_links?ui=s13063-014-0541-9&amp;bibl=B3','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B4">
            <p><a name="B4"></a> de Kraker MEA,  Wolkewitz M,  Davey PG,  Koller W,  Berger J,  Nagler J,  Icket C,  Kalenic S,  Horvatic J,  Seifert H,  Kaasch A,  Paniara O,  Argyropoulou A,  Bompola M,  Smyth E,  Skally M,  Raglio A,  Dumpis U,  Melbarde Kelmere A,  Borg M,  Xuereb D,  Ghita MC,  Noble M,  Kolman J,  Grabljevec S,  Turner D,  Lansbury L,  Grundmann H: <strong> Burden of antimicrobial resistance in European hospitals: excess mortality and length
                  of hospital stay associated with bloodstream infections due to Escherichia coli resistant
                  to third-generation cephalosporins. </strong><p><em>J Antimicrob Chemother</em> 2011,  <strong>66</strong>(2)<strong>:</strong>398-407.  <a target="_blank" href="/pubmed/21106563">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=21106563">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0541-9&amp;bibl=B4" onclick="popup('/sfx_links?ui=s13063-014-0541-9&amp;bibl=B4','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B5">
            <p><a name="B5"></a> Paterson DL,  Ko WC,  Von Gottberg A,  Mohapatra S,  Casellas JM,  Goossens H,  Mulazimoglu L,  Trenholme G,  Klugman KP,  Bonomo RA,  Rice LB,  Wagener MM,  McCormack JG,  Yu VL: <strong> Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production
                  of extended-spectrum beta-lactamases. </strong><p><em>Clin Infect Dis</em> 2004,  <strong>39</strong>(1)<strong>:</strong>31-7.  <a target="_blank" href="/pubmed/15206050">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=15206050">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0541-9&amp;bibl=B5" onclick="popup('/sfx_links?ui=s13063-014-0541-9&amp;bibl=B5','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B6">
            <p><a name="B6"></a> Vardakas KZ,  Tansarli GS,  Rafailidis PI,  Falagas ME: <strong> Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to
                  Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review
                  and meta-analysis. </strong><p><em>J Antimicrob Chemother</em> 2012,  <strong>67</strong>(12)<strong>:</strong>2793-803.  <a target="_blank" href="/pubmed/22915465">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=22915465">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0541-9&amp;bibl=B6" onclick="popup('/sfx_links?ui=s13063-014-0541-9&amp;bibl=B6','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B7">
            <p><a name="B7"></a> Rodriguez-Bano J,  Navarro MD,  Retamar P,  Picon E,  Pascual A: <strong> beta-Lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due
                  to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis
                  of prospective cohorts. </strong><p><em>Clin Infect Dis</em> 2012,  <strong>54</strong>(2)<strong>:</strong>167-74.  <a target="_blank" href="/pubmed/22057701">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=22057701">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0541-9&amp;bibl=B7" onclick="popup('/sfx_links?ui=s13063-014-0541-9&amp;bibl=B7','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B8">
            <p><a name="B8"></a> Peralta G,  Lamelo M,  Alvarez-Garcia P,  Velasco M,  Delgado A,  Horcajada JP,  Montero M,  Roiz MP,  Farinas MC,  Alonso J,  Martinez LM,  Gutierrez-Macias A,  Alava JA,  Rodriguez A,  Fleites A,  Navarro V,  Sirvent E,  Capdevila JA: <strong> Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia
                  coli and Klebsiella spp. bacteremia. A multicentric cohort study. </strong><p><em>BMC Infect Dis</em> 2012,  <strong>12</strong><strong>:</strong>245.  <a target="_blank" href="/pubmed/23038999">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://dx.doi.org/10.1186/1471-2334-12-245">BioMed&nbsp;Central&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0541-9&amp;bibl=B8" onclick="popup('/sfx_links?ui=s13063-014-0541-9&amp;bibl=B8','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B9">
            <p><a name="B9"></a> McLaughlin M,  Advincula MR,  Malczynski M,  Qi C,  Bolon M,  Scheetz MH: <strong> Correlations of antibiotic use and carbapenem resistance in Enterobacteriaceae. </strong><p><em>Antimicrob Agents Chemother</em> 2013,  <strong>57</strong>(10)<strong>:</strong>5131-3.  <a target="_blank" href="/pubmed/23836188">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=23836188">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0541-9&amp;bibl=B9" onclick="popup('/sfx_links?ui=s13063-014-0541-9&amp;bibl=B9','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B10">
            <p><a name="B10"></a> Gupta N,  Limbago BM,  Patel JB,  Kallen AJ: <strong> Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. </strong><p><em>Clin Infect Dis</em> 2011,  <strong>53</strong>(1)<strong>:</strong>60-7.  <a target="_blank" href="/pubmed/21653305">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=21653305">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0541-9&amp;bibl=B10" onclick="popup('/sfx_links?ui=s13063-014-0541-9&amp;bibl=B10','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B11">
            <p><a name="B11"></a> Boucher HW,  Talbot GH,  Benjamin DK Jr,  Bradley J,  Guidos RJ,  Jones RN, <em>et al</em>.: <strong> Infectious Diseases Society of A: 10 × ′20 progress-development of new drugs active
                  against gram-negative bacilli: an update from the Infectious Diseases Society of America. </strong><p><em>Clin Infect Dis</em> 2013,  <strong>56</strong>(12)<strong>:</strong>1685-94.  <a target="_blank" href="/pubmed/23599308">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=23599308">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0541-9&amp;bibl=B11" onclick="popup('/sfx_links?ui=s13063-014-0541-9&amp;bibl=B11','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B12">
            <p><a name="B12"></a> Drawz SM,  Papp-Wallace KM,  Bonomo RA: <strong> New beta-lactamase inhibitors: a therapeutic renaissance in an MDR world. </strong><p><em>Antimicrob Agents Chemother</em> 2014,  <strong>58</strong>(4)<strong>:</strong>1835-46.  <a target="_blank" href="/pubmed/24379206">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=24379206">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0541-9&amp;bibl=B12" onclick="popup('/sfx_links?ui=s13063-014-0541-9&amp;bibl=B12','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B13">
            <p><a name="B13"></a> Tam VH,  Ledesma KR,  Chang KT,  Wang TY,  Quinn JP: <strong> Killing of Escherichia coli by beta-lactams at different inocula. </strong><p><em>Diagn Microbiol Infect Dis</em> 2009,  <strong>64</strong>(2)<strong>:</strong>166-71.  <a target="_blank" href="/pubmed/19304437">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=19304437">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0541-9&amp;bibl=B13" onclick="popup('/sfx_links?ui=s13063-014-0541-9&amp;bibl=B13','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B14">
            <p><a name="B14"></a> Rice LB,  Carias LL,  Hujer AM,  Bonafede M,  Hutton R,  Hoyen C, <em>et al</em>.: <strong> High-level expression of chromosomally encoded SHV-1 beta-lactamase and an outer membrane
                  protein change confer resistance to ceftazidime and piperacillin-tazobactam in a clinical
                  isolate of Klebsiella pneumoniae. </strong><p><em>Antimicrob Agents Chemother</em> 2000,  <strong>44</strong>(2)<strong>:</strong>362-7.  <a target="_blank" href="/pubmed/10639363">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=10639363">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0541-9&amp;bibl=B14" onclick="popup('/sfx_links?ui=s13063-014-0541-9&amp;bibl=B14','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B15">
            <p><a name="B15"></a> Jacoby GA: <strong> AmpC beta-lactamases. </strong><p><em>Clin Microbiol Rev</em> 2009,  <strong>22</strong>(1)<strong>:</strong>161-82.  <a target="_blank" href="/pubmed/19136439">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=19136439">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0541-9&amp;bibl=B15" onclick="popup('/sfx_links?ui=s13063-014-0541-9&amp;bibl=B15','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B16">
            <p><a name="B16"></a> Chen YH,  Hsueh PR,  Badal RE,  Hawser SP,  Hoban DJ,  Bouchillon SK, <em>et al</em>.: <strong> Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli
                  isolated from patients with intra-abdominal infections in the Asia-Pacific region
                  according to currently established susceptibility interpretive criteria. </strong><p><em>J Infect</em> 2011,  <strong>62</strong>(4)<strong>:</strong>280-91.  <a target="_blank" href="/pubmed/21382411">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=21382411">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0541-9&amp;bibl=B16" onclick="popup('/sfx_links?ui=s13063-014-0541-9&amp;bibl=B16','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B17">
            <p><a name="B17"></a> Tzouvelekis LS,  Markogiannakis A,  Psichogiou M,  Tassios PT,  Daikos GL: <strong> Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving
                  crisis of global dimensions. </strong><p><em>Clin Microbiol Rev</em> 2012,  <strong>25</strong>(4)<strong>:</strong>682-707.  <a target="_blank" href="/pubmed/23034326">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=23034326">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0541-9&amp;bibl=B17" onclick="popup('/sfx_links?ui=s13063-014-0541-9&amp;bibl=B17','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B18">
            <p><a name="B18"></a> Rodriguez-Bano J,  Navarro MD,  Retamar P,  Picon E,  Pascual A: <strong> Extended-Spectrum Beta-Lactamases-Red Espanola de Investigacion en Patologia Infecciosa/Grupo
                  de Estudio de Infeccion Hospitalaria G. beta-Lactam/beta-lactam inhibitor combinations
                  for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing
                  Escherichia coli: a post hoc analysis of prospective cohorts. </strong><p><em>Clin Infect Dis</em> 2012,  <strong>54</strong>(2)<strong>:</strong>167-74.  <a target="_blank" href="/pubmed/22057701">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=22057701">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0541-9&amp;bibl=B18" onclick="popup('/sfx_links?ui=s13063-014-0541-9&amp;bibl=B18','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B19">
            <p><a name="B19"></a> Piaggio G,  Elbourne DR,  Pocock SJ,  Evans SJ,  Altman DG,  Group C: <strong> Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT
                  2010 statement. </strong><p><em>JAMA</em> 2012,  <strong>308</strong>(24)<strong>:</strong>2594-604.  <a target="_blank" href="/pubmed/23268518">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=23268518">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0541-9&amp;bibl=B19" onclick="popup('/sfx_links?ui=s13063-014-0541-9&amp;bibl=B19','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B20">
            <p><a name="B20"></a>Breakpoint tables for interpretation of MICs and zone diameters version 4.0. Available
               from: http://www.eucast.org. Accessed 6th December 2014.
            </p>
         </li>
         <li id="B21">
            <p><a name="B21"></a> Paterson DL,  Ko WC,  Von Gottberg A,  Mohapatra S,  Casellas JM,  Goossens H,  Mulazimoglu L,  Trenholme G,  Klugman KP,  Bonomo RA,  Rice LB,  Wagener MM,  McCormack JG,  Yu VL: <strong> International prospective study of Klebsiella pneumoniae bacteremia: implications
                  of extended-spectrum beta-lactamase production in nosocomial Infections. </strong><p><em>Ann Intern Med</em> 2004,  <strong>140</strong>(1)<strong>:</strong>26-32.  <a target="_blank" href="/pubmed/14706969">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=14706969">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0541-9&amp;bibl=B21" onclick="popup('/sfx_links?ui=s13063-014-0541-9&amp;bibl=B21','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B22">
            <p><a name="B22"></a> Chow S-C,  Hansheng W,  Shao J: <em>Sample size calculations in clinical research</em>.  2nd edition.  Chapman Hall, Boca Raton;  2007. <a href="/sfx_links?ui=s13063-014-0541-9&amp;bibl=B22" onclick="popup('/sfx_links?ui=s13063-014-0541-9&amp;bibl=B22','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B23">
            <p><a name="B23"></a>Harris PNA, Mo Y, Jureen R, Chew J, Ali J, Paterson DL, Tambyah PA. Meropenem and
               piperacillin-tazobactam have comparable outcomes in treatment of bloodstream infections
               caused by extended spectrum beta-lactamase producing E.coli and Klebsiellae. Abstract
               number 486, IDWeek. Philadelphia, PA: 8 to 12 October 2014. Available from: https://idsa.confex.com/idsa/2014/webprogram/Paper46679.html.
               Accessed 12th Jan 2015.
            </p>
         </li>
         <li id="B24">
            <p><a name="B24"></a>EUCAST guidelines for detection of resistance mechanisms and specific resistances
               of clinical and/or epidemiological importance. Available from: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_v1.0_20131211.pdf.
               Accessed 26th Jan 2015.
            </p>
         </li>
         <li id="B25">
            <p><a name="B25"></a> Paterson DL: <strong> Determining research priorities for clinician-initiated trials in infectious diseases. </strong><p><em>Med J Aust</em> 2013,  <strong>198</strong>(5)<strong>:</strong>270-2.  <a target="_blank" href="/pubmed/23496404">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=23496404">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0541-9&amp;bibl=B25" onclick="popup('/sfx_links?ui=s13063-014-0541-9&amp;bibl=B25','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B26">
            <p><a name="B26"></a> Spellberg B,  Bartlett JG,  Gilbert DN: <strong> The future of antibiotics and resistance. </strong><p><em>N Engl J Med</em> 2013,  <strong>368</strong>(4)<strong>:</strong>299-302.  <a target="_blank" href="/pubmed/23343059">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=23343059">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0541-9&amp;bibl=B26" onclick="popup('/sfx_links?ui=s13063-014-0541-9&amp;bibl=B26','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
      </ol>
   </div>
</section>
    <br class="clearall">
<div class="article-alert-signup-div">

<a class="close png_bg" id="closeHelpBox" >close</a>	
<div class="article-alert-signup rounded" > 
<span class="blurb left">Sign up to receive new article alerts from <em>Trials</em></span>

	
				<button name="articleAlertPreference.status" type="button" class="w74 right" onClick="window.location='/my/preferences'">Sign up</button>
	
</div>
</div></div>
    </div></div>
</div>


		</div>
</div>

    <hr class="hide" />
	
    

						
   
  
      
  
                  
  
                  
  
            
  
            
            


<div id="footer">

						
			<span class="views"><a id="mobile-view" href="?fmt_view=mobile">Mobile view</a> | <strong>Desktop view</strong></span>
			
	<div class="content">
    <div class="rounded ">
<div class="wrap-inner ">
        	
    <ul class="desktop">
                                                    
				        <li class="noborder"><a href="http://www.biomedcentral.com/about/tandc">Terms and Conditions</a></li>
<li><a href="http://www.biomedcentral.com/about/privacy">Privacy statement</a></li>
<li><a href="http://www.biomedcentral.com/presscenter">Press</a></li>
	<li><a href="http://www.biomedcentral.com/advertisers">Information for advertisers</a></li>
<li><a href="http://www.biomedcentral.com/about/bmcjobs">Jobs at BMC</a></li>
<li><a href="/support">Support</a></li>
<li><a href="/about/contact">Contact us</a></li>


    
    	    </ul>
    <p id="copyright">&copy; 2015 
	BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business&nbsp;Media.</p>
        </div>
</div>

	</div>

</div>
<div class="springer">
    <a href="http://www.springer.com/" target="blank"><img style="float:right; margin:0;" src="
    //www.biomedcentral.com/images/Springer_Branding_footer_logo.png" /></a>
</div>


<script>window.bmcIsMobile = "classic";</script>					    

<script>
// getElementsByClassName Polyfill
var getElementsByClassName=function(e,t,n){if(document.getElementsByClassName){getElementsByClassName=function(e,t,n){n=n||document;var r=n.getElementsByClassName(e),i=t?new RegExp("\\b"+t+"\\b","i"):null,s=[],o;for(var u=0,a=r.length;u<a;u+=1){o=r[u];if(!i||i.test(o.nodeName)){s.push(o)}}return s}}else if(document.evaluate){getElementsByClassName=function(e,t,n){t=t||"*";n=n||document;var r=e.split(" "),i="",s="http://www.w3.org/1999/xhtml",o=document.documentElement.namespaceURI===s?s:null,u=[],a,f;for(var l=0,c=r.length;l<c;l+=1){i+="[contains(concat(' ', @class, ' '), ' "+r[l]+" ')]"}try{a=document.evaluate(".//"+t+i,n,o,0,null)}catch(h){a=document.evaluate(".//"+t+i,n,null,0,null)}while(f=a.iterateNext()){u.push(f)}return u}}else{getElementsByClassName=function(e,t,n){t=t||"*";n=n||document;var r=e.split(" "),i=[],s=t==="*"&&n.all?n.all:n.getElementsByTagName(t),o,u=[],a;for(var f=0,l=r.length;f<l;f+=1){i.push(new RegExp("(^|\\s)"+r[f]+"(\\s|$)"))}for(var c=0,h=s.length;c<h;c+=1){o=s[c];a=false;for(var p=0,d=i.length;p<d;p+=1){a=i[p].test(o.className);if(!a){break}}if(a){u.push(o)}}return u}}return getElementsByClassName(e,t,n)}
</script>

						



<script type="text/javascript">
if (typeof jQuery == 'undefined') { document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.min.js' type='text/javascript'%3E%3C/script%3E")); }


document.documentElement.id = "js";

var site = {
			abbreviation: "",
	        type: "BMC_NICHE",
        portalId: "9001",
                section: "browse",
                page: "fulltext",
    		
									homePortal: "biomedcentral.com",
		
			siteShowAds: "true",
				showAds: "true",
				url: "trialsjournal.com",
			portal: false,
	        adpage_url: "trialsjournal.com/article/10.1186/s13063/014/0541/9",
        id: "10096",
	name: "Trials",
	plugins: {
		scrollable: (getElementsByClassName("scrollable").length > 0),
				flowplayer: ((document.getElementById("flowplayer") != null) || (getElementsByClassName("myPlayer").length > 0) || (document.getElementById("videoarticle") != null) || (getElementsByClassName("flowplayer").length > 0) || (document.getElementById("audio") != null) || (document.getElementById("elifeplayer") != null)),
		lightbox: ((document.getElementById("image-highlight") != null) || (getElementsByClassName("lightbox").length > 0)),
		thickbox: (getElementsByClassName("thickbox").length > 0),
		altmetric: ((document.getElementById("altmetric") != null) || (getElementsByClassName("altmetric").length > 0))
	}
	
};



if(typeof quoteSearchUri == "undefined") { quoteSearchUri=null; }
</script>



        <script type="text/javascript" src="http://www.bmcimg.com/javascript/journals/behaviours-0.js"></script>






		<script>
	if (site.plugins.scrollable == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.scrollable-1.0.1.min.js' %3E%3C/script%3E")); 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.tools.min.js'%3E%3C/script%3E"));
	}

	if (site.plugins.flowplayer == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/flowplayer-3.2.6.min.js'%3E%3C/script%3E"));
	}

	if (site.plugins.lightbox == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/browse_imagehighlight.js'%3E%3C/script%3E"));
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.colorbox.js' %3E%3C/script%3E"));
	}

	if (site.plugins.thickbox == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/thickbox-compressed.js' %3E%3C/script%3E"));
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/thickbox-flashhidden-patch.js' %3E%3C/script%3E"));
	}
	</script>





            <script type="text/javascript" src="http://www.bmcimg.com/javascript/plugins/jquery.fancybox-1.3.1.pack-0.js"></script>
            <script type="text/javascript" src="http://www.bmcimg.com/javascript/plugins/jquery.debug-0.js"></script>
                      <script type="text/javascript" src="http://www.bmcimg.com/javascript/email_preferences/email_preferences-0.js"></script>
                <script type="text/javascript" src="http://www.bmcimg.com/javascript/articles/articles-0.js"></script>
		<div id="fb-root"></div>











        <script type="text/javascript" src="/javascript/plugins/jquery.tagcloud.min-0.js"></script>




<!--[if lte IE 6]>
            <script type="text/javascript" src="/javascript/plugins/DD_belatedPNG_0.0.8a-0.js"></script>
    <script type="text/javascript">
        DD_belatedPNG.fix('.png_bg, ul.primary-nav li a, ul.primary-nav li a span, ul.secondary-nav li a, ul.secondary-nav li a span, ul li i, .plus-button, .facebook, .twitter, .fancy-bg, #fancybox-close');
    </script>
	                <link rel="stylesheet" type="text/css" href="http://www.bmcimg.com/css/hacks/ie6-0.css"/>
    <![endif]-->

<!-- Claudia Whitcombe wanted this comment here -->

       <div class="hide">
      <dl class="google-ad" id="x96banner">
        <dt style="display: block;" class="hide">
          <a class="skyscraper-ad" href="http://www.biomedcentral.com/advertisers/digital_advertising">Advertisement</a>
       </dt>
        <dd>
          <!-- OAS AD 'x96' begin -->
          <script type="text/javascript">
            OAS_AD('x96');
          </script>
        </dd>
      </dl>
    </div>  
    
</body>
</html>

